Published in final edited form as:

J Med Chem. 2013 October 24; 56(20): 7976–7996. doi:10.1021/jm401028t.

Exploration of Allosteric Agonism Structure-Activity Relationships within an Acetylene Series of Metabotropic Glutamate Receptor 5 (mGlu₅) Positive Allosteric Modulators (PAMs): discovery of 5-((3-fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinamide (ML254)

Mark Turlington^{a,b,c}, Meredith J. Noetzel^{a,b}, Aspen Chun^{a,b,c}, Ya Zhou^{a,b,c}, Rocco D. Gogliotti^{a,b,c}, Elizabeth D. Nguyen^f, Karen J. Gregory^{a,b,e}, Paige N. Vinson^{a,b}, Jerri M. Rook^{a,b}, Kiran K. Gogi^{a,b}, Zixiu Xiang^{a,b}, Thomas M. Bridges^{a,b,c}, J. Scott Daniels^{a,b,c}, Carrie Jones^{a,b,c}, Colleen M. Niswender^{a,b,c}, Jens Meiler^{a,d,f,g}, P. Jeffrey Conn^{a,b,c}, Craig W. Lindsley^{a,b,c,d}, and Shaun R. Stauffer^{a,b,c,d,*}

^aDepartment of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, USA

^bVanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232, USA

^cVanderbilt Specialized Chemistry Center for Probe Development (MLPCN), Nashville, TN 37232, USA

^dDepartment of Chemistry, Vanderbilt University, Nashville, TN 37232, USA

^eDrug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052

^fCenter for Structural Biology, Vanderbilt University Medical Center, Nashville, TN 37232, USA

^gVanderbilt Institute for Chemical Biology, Vanderbilt University Medical Center, Nashville, TN 37232, USA

Abstract

Positive allosteric modulators (PAMs) of metabotropic glutamate receptor 5 (mGlu₅) represent a promising therapeutic strategy for the treatment of schizophrenia. Both allosteric agonism and high glutamate fold-shift have been implicated in the neurotoxic profile of some mGlu₅ PAMs; however, these hypotheses remain to be adequately addressed. To develop tool compounds to probe these hypotheses, the structure-activity relationship of allosteric agonism was examined within an acetylenic series of mGlu₅ PAMs exhibiting allosteric agonism in addition to positive allosteric modulation (ago-PAMs). PAM **38t**, a low glutamate fold-shift allosteric ligand (maximum fold-shift ~3.0), was selected as a potent PAM with no agonism in the *in vitro* system used for compound characterization and in two native electrophysiological systems using rat hippocampal slices. PAM **38t** (ML254) will be useful to probe the relative contribution of cooperativity and allosteric agonism to the adverse effect liability and neurotoxicity associated with this class of mGlu₅ PAMs.

*To whom correspondence should be addressed: Tel 615-936-8407, shaun.stauffer@vanderbilt.edu.

SUPPORTING INFORMATION AVAILABLE. mGlu selectivity for **38t**, progressive glutamate fold-shift analysis, pK_B and log_B calculations, DMPK procedures, compound characterization, and NMR data for compounds. This information is available free of charge via the Internet at <http://pubs.acs.org>.

INTRODUCTION

A largely under-met medical need affecting approximately 1% of the world's population, schizophrenia is a complex mental illness characterized by three symptom clusters including positive symptoms (hallucinations, paranoia, disorganized behavior), negative symptoms (social withdrawal, anhedonia, flat affect), and cognitive dysfunction (deficits in attention, learning, and memory).¹⁻⁴ Current treatments for schizophrenia were developed based on the dopaminergic hypothesis of schizophrenia which points to over-activation of subcortical dopamine D₂ receptors as a causative factor for the positive symptoms of the disease.^{5,6} Accordingly, first-generation typical antipsychotics (e.g. haloperidol) act as D₂ antagonists and second-generation atypical antipsychotics (e.g. clozapine, risperidone) act as mixed D₂/5-HT_{2A} antagonists as well as having activity at other receptors.^{5,6} Both classes are routinely used to treat the positive symptoms of schizophrenia and several statistical analyses have revealed that there is little evidence for improved efficacy of atypical over typical antipsychotics except in severe cases of schizophrenia.^{7,8} However, the two classes are different in their side-effect profiles. While typical antipsychotics are plagued by extra-pyramidal side effects (movement disorders) atypical antipsychotics often offer improved side-effect profiles but are associated with significant weight gain.⁸ In addition to the considerable adverse effect profiles, neither class of antipsychotics has a substantial impact on the negative and cognitive symptoms of the disorder, and 20% of patients are non-responsive to treatment.¹ These severe limitations highlight the need to develop new treatments for schizophrenia.

In addition to the dopaminergic pathways, disruptions in many neuronal circuits including the glutamatergic, GABAergic, and cholinergic pathways are observed in schizophrenic patients.³ Importantly, abnormalities in glutamatergic circuits have been linked with all three symptom clusters of schizophrenia, fueling the development of the glutamate hypothesis of schizophrenia as a means to address all symptom clusters. Clinical observations have revealed that phenylcyclidine (PCP) and ketamine, antagonists of the ionotropic N-Methyl-D-aspartate (NMDA) glutamate receptor (NMDAR), produce schizophrenic-like symptoms.^{1-4, 9-13} Furthermore, administration of high doses of the NMDA co-agonists glycine, *D*-serine, and *D*-cycloserine improves positive, negative, and cognitive symptoms in schizophrenic patients,^{1-2, 14-15} generating excitement that enhancement of glutamatergic neurotransmission could be a novel strategy for the treatment of schizophrenic symptoms. While direct activation of NMDAR results in toxicity associated with ion channel overactivation,¹⁻² the metabotropic glutamate receptor 5 (mGlu₅) is closely associated with NMDAR function and may provide an indirect means to rescue NMDAR hypofunction with a lower propensity for toxicity. Numerous studies indicate that mGlu₅ plays a critical role in modulating neurotransmission in forebrain circuits implicated in NMDAR antagonist mediated psychotomimetic effects, and the ability to more subtly modulate NMDAR activity has been proposed to result in a potentially lower propensity for toxicity.^{1-2,4,13,16-17}

mGlu₅ is a member of the Family C G protein-coupled receptors (GPCRs) that bear a large extracellular "Venus flytrap-like" domain that serves as the binding site for glutamate. The high sequence homology of the glutamate binding sites among the eight known metabotropic glutamate receptor (mGlu) subtypes has made the development of subtype selective mGlu₅ orthosteric agonists difficult.^{2,4} In contrast, spatially distinct allosteric binding sites that reside in the transmembrane domain of the receptor (Figure 1) possess less sequence conservation across the mGlu subtypes, making possible the discovery of mGlu₅ selective ligands. Allosteric ligands can activate the receptor directly (allosteric agonists) or can modulate the activity of the receptor in the presence of the endogenous ligand glutamate, either enhancing (positive allosteric modulators, PAMs) or diminishing (negative allosteric

modulators, NAMs) receptor activity.^{18–20} Allosteric modulators with no agonist activity may provide a more subtle and physiologically-relevant approach to restoring target function in comparison to orthosteric/allosteric agonists as receptor response only occurs in the presence of the endogenous agonist.^{18–20} In addition, allosteric modulators often offer improvements in chemical tractability and improved properties for central nervous system (CNS) exposure over traditional orthosteric glutamate analogs, such as quisqualate and (*S*)-3,5-DHPG which have difficulty passing the blood-brain barrier.^{16,18–20}

The advantages of allosteric modulators have fueled the development of highly subtype selective and CNS penetrant mGlu₅ PAMs.^{16–17,21} The earliest mGlu₅ PAMs are represented by the four chemotypes shown in Figure 1. 3,3'-difluorobenzaldazine (DFB), developed by Merck & Co. in 2003, represented the first subtype selective mGlu₅ PAM, and the ensuing discovery of *N*-(4-chloro-2-((1,3-dioxoisindolin-2-yl)methyl)phenyl)-2-hydroxybenzamide (CPPHA) in 2004 provided a compound with improved potency and properties suitable for use in native preparations.²¹ Shortly thereafter, the first highly useful *in vivo* tool compound, 3-cyano-*N*-(1,3-diphenyl-1*H*-pyrazol-5-yl)benzamide (CDPPB) was discovered by Merck scientists,^{22,23} and researchers at Addex Pharmaceuticals reported a chemically distinct mGlu₅ PAM, ADX-47273 (**7**), with suitable properties for *in vivo* studies.²⁴ Utilizing these compounds, studies in animal models have added evidence to the promise of mGlu₅ allosteric activation as a novel therapeutic strategy for the treatment of schizophrenia. PAM **6** has been shown to possess efficacy in animal models predictive of positive symptoms (amphetamine-induced hyperlocomotion (AHL), prepulse inhibition of acoustic startle reflex), cognitive deficits (behavioral and cognitive flexibility, Morris water maze (MWM)), and negative symptoms (sucrose preference).^{16,22–23,36} Studies with **6** have revealed similar efficacy in reversal of positive symptoms (conditioned avoidance responding, apomorphine-induced climbing, AHL) and improvements in cognition (novel object recognition, five-choice serial reaction time test, MWM).^{16,24,36} In the wake of these studies, numerous novel mGlu₅ PAM chemotypes have been discovered and optimized, leading to improvements in potency and physiochemical properties.^{16,17} Representatives of major chemotypes are shown in Figure 2 and many of these compounds have demonstrated efficacy in antipsychotic and cognition models.^{27–36} In addition, Lilly recently revealed mGlu₅ PAMs LSN2814617 (**10**) and LSN2463359 (**14**).²⁸ Both **10** and **14** are reported to shift a concentration-response curve for the group I orthosteric agonist, DHPG, in rat cortical neurons with relatively weak efficacies compared to historical mGlu₅ PAMs (**10**, FS = 2.8 at 3 μM; **14**, FS = 2.0 at 1 μM). *In vivo*, these compounds have been reported to exert significant effects in multiple models including: methylazoxymethanol (MAM) neurodevelopmental model of schizophrenia, wake-promoting properties in acute sleep-wake electroencephalogram (EEG), and reversal of NMDAR antagonist SDZ 220,581-induced disruptions in delayed matching-to-position (DMTP).²⁸ Interestingly, these low efficacy PAMs do not substantially impact baseline performance on their own in DMTP, nor do they have significant effects in reversal of hyperlocomotion in the AHL model, which is in contrast to previously reported mGlu₅ PAMs that maintain higher efficacies (orthosteric agonist concentration-response curve EC₅₀ fold-shift greater than 3.0).^{17,23–25,30,33,36}

Despite the therapeutic promise of mGlu₅ PAMs, recent findings have begun to reveal a CNS adverse-effect (AE) liability for certain classes of mGlu₅ PAMs.^{37–39} The seizure-inducing effects of group I mGlu orthosteric agonists is well known^{40,41}; however, the potential for mechanism-related AEs associated with *allosteric* mGlu₅ receptor activation was not appreciated until recently. Studies in our laboratories have demonstrated that allosteric modulator **19** (VU0424465, ML273, Figure 3) causes seizure activity in rodents.³⁷ This effect can be blocked by treatment with 2-methyl-6-(2-phenylethynyl) pyridine (MPEP), an allosteric mGlu₅ NAM, pointing to the role of mGlu₅ in the observed neurotoxicity. Our recombinant mGlu₅ cell line with low receptor density is predicted to

have a better correlation with the functional response observed in native systems and thus serves as a more definitive assay system to detect allosteric agonism.⁴³ Allosteric modulator, **19** displays both allosteric agonism and PAM activity (ago-PAM activity) in a mGlu₅ cell line with low receptor density, as well as in native systems such as astrocytes.³⁷ In contrast, nicotinamide acetylene allosteric modulator **20** (VU0361747, Figure 3) was devoid of agonism in these low-expressing mGlu₅ cells and did not display a seizure liability *in vivo*.³⁷ Thus, allosteric agonist activation of mGlu₅, similar to orthosteric activation, can contribute to an AE liability *in vivo* and epileptogenesis in native systems. Further evidence in support of this hypothesis surfaced from profiling of **21** (VU0403602, Figure 3). Similarly to ago-PAM **19**, picolinamide acetylene **21** demonstrates agonist activity in a mGlu₅ low-expressing cell line and native systems and possesses a seizure liability in animal models.³⁸ Further complicating the pharmacological effects of **21**, its principle *in vivo* metabolite **22** (VU0453103) also displays significant ago-PAM activity, suggesting that formation of active metabolites is possible and may contribute to an adverse effect profile *in vivo*. These findings highlight the need to avoid an ago-PAM pharmacological profile in both the parent compound and its major metabolites in the quest to develop allosteric ligands for mGlu₅ receptor activation.

Concurrent with these findings, a collaborative effort between Merck and Addex Pharmaceuticals revealed that mGlu₅ PAMs within their piperidine and caprolactam chemotypes induced significant convulsions and neuronal cell death in mice (Figure 4).³⁹ In contrast mGlu₅ knock-out mice that were administered the compounds did not display these adverse effects. These compounds did not possess ago-PAM activity in astrocytes suggesting allosteric agonism is not necessarily required to induce adverse effects; although the pharmacological profile of the major metabolites was not reported. While the most toxic compound reported 5PAM523 (**23**, Figure 4) had a therapeutic index of just 2-fold (C_{max} minimum active dose amphetamine-induced hyperlocomotion versus C_{max} minimum adverse effect dose), higher therapeutic indices were observed for the additional compounds reported. Of these, 5PAM916 (**24**) was found to have the highest therapeutic index (18-fold) and the lowest glutamate EC₅₀ fold-shift (6-fold at 10 μM). These observations suggest that the efficacy to shift a glutamate concentration-response curve, or more precisely PAM cooperativity, may play an important role in neurotoxicity, such that improved safety margins may be realized by designing compounds possessing lower cooperativity.³⁹

These reports, along with the adverse effect liability of allosteric agonism observed in our laboratories, suggest that PAMs devoid of agonism in situations where mGlu₅ expression is low and possessing moderate to low efficacy may be preferable for developing compounds with optimal safety margins. To further investigate the safety implications of ago-PAM pharmacology we initiated medicinal chemistry efforts to explore the structural determinants of ago-PAM activity in the **19** scaffold.³⁷ We targeted the development of highly potent (10 nM) tool compounds structurally similar to **19** that did not exhibit allosteric agonism in our *in vitro* assay systems. In addition, the glutamate fold-shift profile of promising pure PAMs was also investigated as an indicator of cooperativity. Herein we report a detailed structure-activity relationship (SAR) of allosteric agonism within this class of acetylene based mGlu₅ PAMs. This study led to the optimization and characterization of low cooperativity PAM acetylenes that possess *in vitro* pharmacological and pharmacokinetic profiles that will enable further studies to address ongoing questions concerning the therapeutic index of mGlu₅.

RESULTS AND DISCUSSION

Structure-Activity Relationship (SAR) Design

Our development of acetylenic mGlu₅ PAMs originated with a high throughput screen (HTS) lead VU0092273 (**25**, Figure 5) that was quickly optimized to the nicotinamide analog, VU0360172 (**26**, Figure 5).⁴² The introduction of the central pyridyl ring in **26** enabled salt formation leading to improved water solubility and the first orally active acetylene mGlu₅ PAM, despite a high degree of plasma protein binding (98.9%) and low CNS exposure (brain to plasma ratio = 0.13). Subsequent efforts to improve physiochemical properties within this class led to the discovery that picolinamide analogs, as represented by **21** (Figure 5),³⁸ which show a general improvement in potency, still possess a high degree of plasma protein binding (>99% bound in human and rat). Both **21** and **26** were found to undergo substantial oxidative metabolism of the eastern cyclobutane ring (see Figure 3).³⁸ With these findings we turned our efforts toward reducing lipophilicity and addressing metabolism of the eastern alkyl group through the introduction of functional groups bearing additional hydrogen bond donors and/or acceptors in this portion of the molecule. This effort led to the discovery of **19** bearing a tertiary carbinol which contributed to improved solubility, reduced metabolism, and reduced plasma protein binding (2.8% bound in rat, 2.7% bound in human).

As **19** represented one of the first compounds within the acetylene class to possess ago-PAM activity in the lowexpressing receptor cell line,³⁷ we initiated exploration of SAR around this analog to probe the structural determinants of allosteric agonism. Analysis of **19** yielded three important structural features to explore: the western aryl ring, the heteroaryl core, and the eastern amide region. The western aryl ring was hypothesized to be a structural region that might impact *in vitro* PAM to NAM profile mode switching as observed in related acetylenes.¹⁷ The importance of the core region was suggested by the fact that nicotinamide containing acetylenes **26** and **20** were active as PAMs but devoid of agonist activity (Figures 3 and 5). Lastly, the hydroxyl motif in the eastern amide region of **19** and metabolite **22**³⁸ was identified as a common structural motif among acetylenes possessing adverse effect profiles; therefore, alternate functional groups designed to maintain good pharmacokinetic and physiochemical properties were targeted.

Chemistry

To explore western aryl and core analogs (*R*)-3-amino-2-methylbutan-2-ol, **29**, was first prepared as shown in Scheme 1.³⁵ Starting from (D)-alanine, the amino acid was transformed into the methyl ester upon treatment with SOCl₂ in MeOH. Protection of the amine as the *tert*-butyl carbamate yielded intermediate **27** in 88% yield over the 2 steps. Reaction with MeMgBr (3.0 equiv.) yielded tertiary alcohol **28** in 63% yield, and deprotection in the presence of TFA/CH₂Cl₂ afforded (*R*)-3-amino-2-methylbutan-2-ol, **29**. While the amino alcohol could be stored as the TFA salt and used over a period of several weeks, best results were obtained by removing the *tert*-butyl carbamate immediately prior to use.

The desired analogs to explore the structural properties of compounds possessing allosteric agonism were accessed in the parallel synthetic sequences shown in Schemes 2–4. The western aryl region was rapidly diversified utilizing key intermediates **30** and **33**. 5-Bromopicolinamide **30** was accessed via a HATU mediated amide coupling of 5-bromopicolinic acid with **29** in 81% yield. Palladium catalyzed Sonogoshira coupling of **30** with aryl and cyclic alkyl acetylenes provided the desired western analogs **31** in 50–90% yield. When the desired acetylene coupling partners were unavailable, analogs were synthesized from terminal acetylene **33**. Sonogoshira coupling of 5-bromo-picolinamide **30** with

trimethylsilylacetylene to yield **32**, followed by removal of the silyl protecting group with K_2CO_3 in MeOH/THF provided terminal acetylene **33** in 73% yield over 2 steps. Sonogoshira coupling of the resulting terminal acetylene with aryl and heteroaryl bromides provided the desired analogs in 43–62% yield.

Synthesis of heteroaryl core analogs was achieved as displayed in Scheme 3. Sonogoshira coupling of 4-bromoheteroaryl carboxylic acids **34a** and 1-ethynyl-3-fluorobenzene yielded biaryl acetylenes **35a** in 30–97 % yield, which were then subjected to a HATU mediated amide bond coupling with **29** to access core analogs **36**. Where the desired carboxylic acids were not available the corresponding esters **34b** were used to access intermediate **34b** via a Sonogoshira coupling with 1-ethynyl-3-fluorobenzene. Saponification of ester **35b** with LiOH in THF/H₂O and amide coupling with **29** yielded the desired analogs.

The eastern amide region was explored utilizing ethynyl-picolinic acid **37** as shown in Scheme 4. Following coupling of 5-bromopicolinic acid with 1-ethynyl-3-fluorobenzene to yield **37**, a variety of amines were installed through HATU mediated amide bond formation. To understand the effect of the chiral center, (*S*)-3-amino-2-methylbutan-2-ol was prepared from L-alanine in a sequence analogous to that shown in Scheme 1, and a variety of commercially available chiral amines bearing the (*R*)- and (*S*)-configuration at the chiral center were investigated. In addition, to systematically explore the effects of the eastern hydroxyl on ago-PAM activity several additional analogs were prepared directly from **19**. Methylation of the tertiary hydroxyl by treatment with NaH in THF followed by reaction with MeI afforded methyl ether **38f**. The hydroxyl group was also transformed into the corresponding fluoro-analog via reaction of the alcohol with DAST (CH₂Cl₂, –78 °C) to access **38e**.

In Vitro Pharmacology

Compounds were profiled in our rat mGlu₅ low receptor expression cell line using a “triple add” protocol in accord with previously published procedures.^{42,43} Activity observed using the low receptor expressing cell line correlates with the functional response observed in native systems and allows for detection of allosteric agonism. The “triple add” protocol allows compounds to be evaluated for agonism as well as positive and negative allosteric modulation simultaneously.⁴³

The structure-activity relationship (SAR) are shown in Tables 1–3. SAR around the western aryl region reveals that most manipulations to this portion of the molecule do not eliminate ago-PAM activity. As seen in compounds **19** and **31b–31c**, positioning of the fluorine atom only modestly affected potency and efficacy with des-fluoro compound **31a** and 3-fluoro congener **19** preferred for both agonist and PAM potency. Incorporation of the sterically larger methyl group led to a concomitant decrease of PAM and agonist activity, except in the case of *meta*-substituted analog **31g**. While agonism was retained for *ortho*- and *meta*-substituted derivatives **31f** and **31g**, methyl substitution at the *para*-position led to PAM **31h**. Introduction of a western pyridyl also proved to impact agonist activity, leading to the discovery of PAM **31i**, bearing a western 2-pyridine. Structurally, **31i** is intriguing as PAM to NAM mode switching has been observed upon the introduction of the 2-pyridyl functionality within the tetralone acetylene series reported by Merz Pharmaceuticals²⁹ and in the acetylene scaffold by reported by Ritzen and coworkers (Figure 6).^{31,44} Thus, it appears that, within the acetylene scaffold, the 2-pyridyl functionality can engender inhibitory effects in some cases. Moreover, when functionalities are present in other regions of the molecule that lead to receptor activation (e.g. agonism or ago-PAM) the 2-pyridyl group appears to moderate these strong agonist effects. The positioning of the pyridyl nitrogen also appears to be critical for attenuation of the agonism, as the 3- and 4-substituted

pyridines (**31j**, **31k**) maintain ago-PAM activity. Given that the 2-pyridiyl motif is structurally reminiscent of mGlu₅ antagonist MPEP, we also investigated the methyl thiazole motif found in the mGlu₅ antagonist MTEP to give **31l**, which also elicited a PAM profile with no observed agonism. Finally, cyclic alkyl groups were explored, with cyclopropyl derivative **31m** found to be a PAM, although with greatly reduced potency. Ago-PAM cyclopentyl derivative **31n** exhibited a smaller degree of allosteric agonism relative to aryl analogs.

In parallel, explorations of the core region of the molecule revealed interesting structural features of allosteric agonism. Deletion of the nitrogen in benzamide **36a** yielded a highly potent ago-PAM. Interestingly, although nicotinamide analog **36b** displayed reduced potency in comparison with picolinamide **19** it still displayed significant allosteric agonism. As nicotinamide acetylene analogs exemplified by **20** (Figure 3) and **26** (Figure 5) are generally PAMs devoid of agonism, these results suggest that the eastern amide portion of the molecule is partially responsible for the observed allosteric agonism. Core modifications were able to eliminate allosteric agonism in some instances, as 3- and 4-substituted methyl analogs **36d** and **36e** as well as pyrimidine **36f** were found to lack apparent agonist activity. Regioisomeric pyrimidine **36g**, however, displayed ago-PAM activity, as did pyridazine, pyrazine, and thiazole core analogs (**36h-36j**).

We next turned our attention to exploring the eastern amide region within the picolinamide core as this structural motif appeared to have a significant bias toward ago-PAM activity. Maintaining the propyl backbone found in **19**, we prepared a number of analogs, systematically varying substituents to explore the SAR profile of allosteric agonism. Based on our initial hypothesis that the tertiary carbinol contributes to allosteric agonism and adverse effects, our first round of SAR involved deletion and modification of the tertiary hydroxyl. Surprisingly, *tert*-butyl analogs **38a** and **38b** and *iso*-propyl analogs **38c** and **38d** displayed potent ago-PAM activity and replacement of the hydroxyl with fluorine (**38e**) resulted in a potent ago-PAM.

For optically active compounds **38a-38d** a slight preference was observed for the (*R*)-enantiomer. Interestingly, capping the tertiary carbinol as the methyl ether (**38f**) resulted in an inactive compound. As changes to the tertiary carbinol were not successful in preventing ago-PAM activity, we deleted the methyl group adjacent to the amide while maintaining the eastern alkyl chain carbon backbone length found in **19**. This exploration proved fruitful with *iso*-butyl analog **38h** and methyl-cyclopropyl analog **38j** found to be potent PAMs; however, the effect was subtle and the trend was not entirely clear as the propyl analog **38g**, *tert*-butyl analog **38i**, and the methyl-cyclobutyl analog **38k** displayed weak agonism.

Since deletion of the tertiary carbinol did not yield a general strategy to prevent allosteric agonism, we next explored analogs bearing the eastern alcohol in order to gain an understanding of the SAR of allosteric agonism when a hydrogen bond donor was maintained. The effect of the configuration of the chiral center was first explored and, surprisingly, the opposite enantiomer of **19**, (*S*)-**38l**, was inactive, suggesting that the position of the tertiary hydroxyl group is critical in receptor activation at the allosteric binding site. In contrast, both enantiomers of optically active derivatives **38a** to **38d** were active ago-PAMs, with only a slight preference for the (*R*)-enantiomer. Removal of steric bulk surrounding the alcohol (**38m**) and adjacent to the amide (**38n**) did not remove allosteric agonism, while alcohol **38o** possessing no steric bulk was inactive. Interestingly, extension of the carbon backbone in analog **38p** resulted in a loss of agonist activity, suggesting that allosteric agonism within this series is sensitive to the location of the tertiary alcohol.

We next pursued alternatives to the tertiary alcohol, investigating functional groups that conceptually could serve as a “molecular lock”, such that the functionality possesses desirable physiochemical and DMPK properties, which intentionally deter formation of hydroxylated metabolites specifically within the eastern amide moiety that may engender undesirable pharmacology on their own.³⁹ Fluorinated alkyl amides were explored, and trifluoroethyl derivative **38q** was found to be an ago-PAM with moderate potency. Trifluoroalkyl derivatives possessing a chiral center afforded increased activity (**38r–s**). Interestingly, these analogs yielded enantiospecific activity, with (*R*)-**38r** representing a highly potent PAM and (*S*)-**38s** displaying ago-PAM activity. We also explored oxetanes since this motif has been utilized as a surrogate for geminal dimethyl groups and represent a polar alternative for the introduction of steric bulk as well as possessing hydrogen bond accepting properties.⁴⁵ In particular, the oxetane was appealing as a means to address the high lipophilicity and plasma protein binding associated with our recently reported PAM VU0405386 (**43**);⁴⁶ thus, we prepared the 3-methyl substituted oxetane as a *tert*-butyl replacement (**38t**, Figure 7). The oxetane can also be envisioned as an isosteric replacement for the cyclobutyl moiety found in **21** (Figure 3), which was found to generate the 3-hydroxy metabolite **22** (Figure 3) that contributed in part to an adverse effect profile. Incorporation of the oxetane moiety proved successful and **38t** represents the most potent PAM (EC₅₀ = 9.3 nM) discovered thus far within this series. Maintaining the oxetane and extending the carbon chain length one carbon led to equipotent PAM **38u**. Further extension to the two carbon variant **39v** maintained potentiation activity; however, weak allosteric agonism returned (EC₅₀ = 2.8 μM, Glu Max 16.3%). Collectively, the eastern amide SAR strongly suggests that the general structural elements of the 2-methylbutan-2-ol motif (**29**) introduced to increase solubility are strongly biased toward allosteric agonism and that other eastern amide groups can be identified with favorable physiochemical properties that result in PAMs lacking agonist activity.

In light of these results, a final round of SAR was pursued to probe the effects of the basicity of the pyridyl nitrogen in pure PAM **31i** and to investigate combination of the western pyridyl with a small subset of eastern alkyl groups such as the oxetane motif. We first studied the effects of the basicity of the pyridyl nitrogen through the introduction of electron withdrawing fluorine atoms around the pyridine ring. If a basic nitrogen at the 2-position of the pyridine ring helps to stabilize a conformation of the receptor not disposed toward allosteric agonism, we hypothesized that decreased basicity of the pyridyl nitrogen at this position might weaken this interaction and restore allosteric agonism. As shown in Table 5, introduction of fluorine reveals that the basicity of the pyridyl nitrogen is in fact important, as fluoro-substituted pyridyls **31o** – **31r** display allosteric agonism. We subsequently designed several analogs to explore whether the 2-pyridyl functionality could serve as a “molecular lock” to prevent allosteric agonism in compounds bearing eastern amide alkyl groups found to possess agonism when combined with the 3-fluorophenyl western aryl ring. This study revealed that the 2-pyridyl motif prevented allosteric agonism in some but not all cases. Modulator **44b** and **44c** exhibited PAM activity; however, *tert*-butyl analog **44a** displayed ago-PAM activity. We then pursued a hybrid picolinamide acetylene containing the western 2-pyridyl and eastern oxetane amide motifs since these substructures were discovered to be two of the most preferred structural elements to maintain PAM activity without apparent agonism (**44d**). Unexpectedly, this combination led to mode switching, yielding an antagonist. Moving the nitrogen to the 4-position and maintaining the oxetane (**45**) restored some potentiation, resulting in a weak PAM.

In an effort to gain further insights into the interaction of ago-PAM versus PAM preferring functional groups within the mGlu₅ binding pocket PAMs **31i** and **38t** along with ago-PAM **19** were docked into our recently generated comparative model of the transmembrane region of mGlu₅ (Figure 8).⁴⁷ Interestingly, in comparison with previously docked picolinamide

PAMs (e.g. **43** and **21**),⁴⁷ all three compounds sit higher in the binding pocket; this may be attributable to the inclusion of the additional hydrogen bond acceptor on the eastern amide. Similar to what we observed for other acetylenic PAMs, computationally it was difficult to differentiate whether the eastern amide is buried deep within the pocket, or points towards the extracellular space, likely a reflection of the highly linear structure for the class. However, models wherein the eastern amide points towards the extracellular space placed the compounds in proximity of residues previously found to be critical for the function of acetylene PAMs and MPEP (Figure 8).⁴⁷ The hydroxyl and amide carbonyl of the modulators were within 3 Å of S808 and the 2-pyridyl western aryl ring was within 3 to 5 Å from Y658, T780 and W784. This pose was chosen as the most likely binding conformation due to its consistency with existing data, and the second possible pose is shown in the Supplementary Material (see section VI).

In an attempt to probe these putative poses and elucidate the molecular determinants of agonism further, we examined the impact of four key point mutations (Y658V, T780A, W784A and S808A) on modulator affinity, cooperativity and agonism by applying an operational model of allosterism to glutamate concentration-response curves in the absence and presence of varying concentrations of each PAM, i.e. a progressive fold-shift experiment (Supplementary Material, see sections II–V). All three compounds were sensitive to alanine substitution of T780A; however, the observed reductions in affinity (10–30 fold) were not as substantial as those reported for previous picolinamides (e.g. **43** and **21**).⁴⁷ The overall profile of **38t** across all four point mutations was comparable to the prior picolinamides,⁴⁷ and in particular both Y658V and S808A engendered a NAM switch identical to previously reported (5-((3-fluorophenyl)ethynyl)pyridin-2-yl)(3-hydroxyazetidin-1-yl)methanone (VU0405398).⁴⁷ The most striking differences are observed for **31i**, as Y658V had no effect on affinity or cooperativity, despite causing marked reductions in affinity, including abolishment of PAM activity, for all other picolinamide PAMs tested to date. Furthermore, **31i** showed a gain in allosteric agonist activity at W784A, a mutation known to reduce the negative cooperativity of MPEP and increase positive cooperativity of other PAMs.⁴⁷ Based upon the pose depicted in Figure 8 and the 2-pyridyl “molecular switch” trends discussed previously (*vide supra*, see Figure 6), it may be hypothesized that the 2-pyridyl western aryl within acetylenic mGlu₅ modulators has a key interaction with W784, favoring less active receptor states. In the W784A mutant where this interaction is absent, modulator **31i** more readily facilitates active receptor conformations.

Having gained insights into the allosteric agonism SAR and potential models for receptor/residue-ligand interaction, we turned our attention to PAM glutamate cooperativity due to its impact on therapeutic index. We selected PAMs lacking agonist activity from this investigation that display potency values > 200 nM and evaluated their ability to left shift the glutamate concentration-response curve at a concentration of 10 μM (Table 6). This analysis revealed a range of glutamate fold-shift values from 1.3 to 5.3-fold. This distribution of fold-shift values provides useful tool compounds to probe the impact of cooperativity on therapeutic index in PAMs within the biaryl acetylene chemotype. Due to its excellent potency and low cooperativity, PAM **38t** was selected for further characterization and declared an MLPCN probe.

To validate that **38t** interacts with mGlu₅ at the MPEP binding site radioligand binding studies were performed with [³H]methoxyPEPy. Increasing concentrations of **38t** resulted in complete inhibition of [³H]methoxyPEPy binding supporting a competitive interaction between the two ligands (Figure 9). **38t** exhibited a K_i of 90 nM, representing a ~10-fold higher functional activity (EC₅₀ = 9.3 nM) compared to binding. To utilize compounds in *in vivo* assays it is important to determine if they are selective for mGlu₅ compared with other

mGlu subtypes. A 10 μM concentration of PAM **38t** did not shift the glutamate (or L-AP4) concentration response curve when evaluated using cells expressing any of the other mGlu subtypes (mGlu₁₋₄, ₆₋₈, see Supplementary Material section I) demonstrating high selectivity for mGlu₅. In addition, screening of 10 μM **38t** against a panel of 68 GPCRs, ion channels and transporters revealed no significant off target activity (Eurofins Inc.). Finally, oxetane **38t** was evaluated in progressive fold-shift experiments (50 nM to 30 μM). The shift in the glutamate concentration response curve in the presence of increasing concentrations of modulator is shown in Figure 10. Increasing concentration of modulator resulted in a fold-shift that reached a maximum of approximately 3.0-fold at 5 μM with a predicted affinity of -6.81 (154 nM) and an efficacy cooperativity factor ($\log\beta$) between glutamate and indicated allosteric modulator of 0.34 (cooperativity ~ 2.2).

The *in vitro* drug metabolism and pharmacokinetic (DMPK) profile of **38t** was next determined, with the hope that the oxetane motif would help to mitigate previously observed metabolism and improve physiochemical properties within this chemotype. Gratifyingly, oxetane **38t** displayed low *in vitro* metabolism with a predicted hepatic clearance (CL_{HEP}) of 1.6 mL/min/kg in rat and 0.2 mL/min/kg in human, a significant improvement in comparison to similar compounds within this series (**19**: predicted CL_{HEP} of 34.5 mL/min/kg in rat and 3.5 mL/min/kg in human; **21**: predicted CL_{HEP} of 55.6 mL/min/kg in rat³⁸). PAM **38t** also possesses improved fraction unbound (f_u) as measured by plasma protein binding assay using equilibrium dialysis, with oxetane **38t** 3.5% unbound in human plasma and 3.6% unbound in rat plasma. In comparison, more lipophilic **21** displays human and rat f_u plasma values $< 1\%$.³⁸ Rat brain homogenate binding was used to determine fraction unbound in brain for **38t**; these studies revealed f_u brain values of 1.6%. To assess drug-drug interactions, inhibition of the major human cytochrome P450 (CYP) enzymes (2C9, 2D6, 3A4, 1A2) was measured in human liver microsomes and **38t** was found to display inhibitory activity at 1A2 ($\text{IC}_{50} = 5.30 \mu\text{M}$) while no activity was observed against the other CYPs tested ($\text{IC}_{50} > 30 \mu\text{M}$). Solubility of **38t** was found to be modest with a Fassif (fasted simulated intestinal fluid) solubility of 10–23 $\mu\text{g/mL}$.

To verify its PAM pharmacological profile in native systems **38t** was examined for induction of long-term depression (LTD) at the Schaffer collateral – CA1 (SC-CA1) synapse in the hippocampal formation. LTD at this synapse is known to be modulated by mGlu₅ activation, and orthosteric mGlu₅ agonists such as (*S*)-3,5-DHPG have been shown to elicit LTD.⁴⁸ Similarly ago-PAM **19** induces LTD;³⁸ however, **38t** does not induce LTD on its own (Figure 11; $100.3 \pm 3.7\%$ baseline 55min after compound washout). This provides further evidence that **38t** does not elicit a response on its own in native systems. In addition, prior studies involving **19** showed the induction of epileptiform activity in CA3 pyramidal neurons in hippocampal preparations. We performed similar studies with **38t** to assess agonist activity in this native CNS preparation. PAM **38t** had no significant effect on either the inter-event interval ($127.9 \pm 7.7\%$ of baseline) or amplitude ($101.2 \pm 5.0\%$ of baseline) of spontaneous firing supporting an agonism-free profile for **38t** (data not shown). These data demonstrate that **38t** acts as a pure PAM in two hippocampal native systems.

CONCLUSION

Although mGlu₅ PAMs represent a promising therapeutic strategy for the treatment of schizophrenia, recent reports have raised concerns over a seizure liability and neurotoxicity associated with some chemotypes. Allosteric agonism within the **19** acetylenene chemotype and a high cooperativity (glutamate fold-shift) within the Merck-Addex piperidine and caprolactam series are pharmacological profiles that have been associated with an adverse effect liability. We have extensively explored the SAR of allosteric agonism within the acetylene amide chemotype providing insight into the structural elements contributing to

allosteric agonism. In general, the structural elements of the eastern amide were found to have the greatest impact on the presence or absence of allosteric agonism. Replacement of the western 3-fluorophenyl with the 2-pyridyl motif was found to eliminate allosteric agonism in many but not all cases. The computational docking and mutagenesis data highlight the subtleties of interactions within the common allosteric site, wherein key residues, in particular W784 and S808, are hypothesized to be engaged in key interactions important for receptor-modulator interaction and function. Future studies to understand if the functional consequences of these mutants are indicative of a direct residue side-chain-modulator interaction, or an indirect allosteric interaction will be important to pursue.

Due to the potential impact of cooperativity on adverse effects the glutamate fold-shift profile of potent PAMs was examined revealing PAMs possessing low to moderate efficacy as assessed by glutamate fold-shift. This distribution of cooperativity profiles will enable studies to test the impact of glutamate fold-shift on neurotoxicity within this chemotype. Based on its efficacy profile and lack of apparent agonism *in vitro*, highly potent oxetane **38t** was further characterized and found to possess significantly improved DMPK properties compared with other acetylenes within this series. **38t** was also profiled in native systems and exhibited no allosteric agonism for the induction of LTD at the Schaffer collateral – CA1 (SC-CA1) synapse or epileptiform activity in CA3 pyramidal neurons. Preliminary experiments using a high dose of **38t** in an *in vivo* model of psychosis demonstrate robust reversal of amphetamine induced hyperlocomotion (data not shown) with no overt behavioral disturbances; however, definitive PK-PD studies in this and other models, including fluorojade neurotoxicity studies, are needed in order to fully ascertain the anticipated *in vivo* properties of PAM **38t**. PAM **38t** represents a highly potent tool compound with acceptable pharmacokinetic properties that will enable further studies to probe the therapeutic index of low fold-shift PAMs. Such studies involving **38t** and other structurally diverse PAMs are underway and will be reported in due course. mGlu₅ PAM **38t** (ML254) is an MLPCN probe and is freely available upon request.⁶⁰

EXPERIMENTAL SECTION

General

All reagents purchased from commercial suppliers were used without purification. Unless noted all solvents used were anhydrous and all reactions were carried out under argon atmosphere. Analytical thin layer chromatography was performed on Analtech silica gel GF 250 micron plates. Preparative RP-HPLC purification was performed on a Gilson Inc. preparative UV-based system using a Phenomenex Luna C18 column (50 × 30 mm I.D., 5 μm) with an acetonitrile (unmodified)–0.1% trifluoroacetic acid in water gradient. Normal-phase silica gel preparative purification was performed using an automated Combi-flash Rf from ISCO. Analytical LC/MS was performed on an Agilent 1200 Series with UV detection at 215 and 254 nm and ELSD detection (Polymer Laboratories PL-ELS 2100), utilizing an Accucore C18 2.6μ, 2.1 × 30 mm column, a 1.1 min gradient, 7% [CH₃CN/ 0.1% TFA] – 95 [CH₃CN/ 0.1% TFA] and a G6130 single quadrupole mass spectrometer. Purity of all final compounds was determined to be >98% by analytical HPLC. Solvents for extraction, washing and chromatography were HPLC grade. NMR spectra were recorded on a Bruker 400 MHz spectrometer.¹ H chemical shifts are reported as δ values in CDCl₃ or CDOD₃. Data are reported as follows: chemical shift, integration, multiplicity (s = singlet, bs = broad singlet, d = doublet, t = triplet, q = quartet, p = pentet, hex = hextet, sep = septet, dd = doublet of doublets, dq = doublet of quartets, m = multiplet), coupling constant reported in Hz.¹³ C chemical shifts are reported in δ lues in CDCl₃ or CDOD₃ as follows: chemical shift, C–F coupling constants (*J*_{C–F}) reported in Hz. Low resolution mass spectra were obtained on an Agilent 1200 series 6130 mass spectrometer. HRMS were obtained using a

Micromass (Waters) Q-ToF API-US calibrated and verified with sodium iodide. The samples were diluted with a 50:50 0.1% Formic Acid (in Milli-Q):Acetonitrile solution, directly infused using Leucine-Enkephalin (M+H=556.2771) as a lockmass. Scan range was from 100–1000 Da, using a scan time of one second. The [M+H] or [M+Na] ion was observed. Optical rotation values were obtained on a JASCO P-2000 polarimeter.

Chemistry

(R)-*t*-Butyl (3-hydroxy-3-methylbutan-2-yl)carbamate (28)—(D)-Alanine (15 g, 0.168 mol, 1 equiv) was dissolved in MeOH (75 mL, 2.2 M) and cooled to 0 °C. SOCl₂ (20.8 mL, 0.286 mol, 1.7 equiv) was *slowly* added taking care to control the exotherm. The reaction mixture was stirred overnight warming to room temperature. After the reaction was determined to be complete by TLC, the MeOH and excess SOCl₂ were carefully removed by vacuum distillation. The resulting oil was redissolved in MeOH (50 mL) and the solvent was removed by rotary evaporation. The resulting methyl ester was dissolved in CH₂Cl₂ (150 mL, 1.1 M) and cooled to 0 °C. Et₃N (70.2 mL, 0.504 mol, 3 equiv) and Boc₂O (44 g, 0.202 mol, 1.2 equiv) were added and the reaction mixture was allowed to warm to room temperature and stirred overnight. After the reaction was determined to be complete by TLC, the precipitates formed during the reaction were removed via filtration through celite rinsing with CH₂Cl₂. The organic layer was washed with citric acid (sat'd aq, 1 × 50 mL), dried with Na₂SO₄, and concentrated via rotary evaporation yielding (R)-methyl 2-((tert-butoxycarbonyl) amino)propanoate as a yellow oil (30 g, 88% yield). [α]_D²⁰ = 3.6 (c = 1.3, CHCl₃); ¹H NMR (400MHz, CDCl₃) δ 5.07 (1H, bs), 4.28 (1H, m), 3.71 (3H, s), 1.41 (9H, s), 1.35 (3H, d, *J* = 7.2 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 173.8, 155.0, 79.7, 52.2, 49.1, 28.2, 18.5; HRMS (ES+, M+H) calcd for C₉H₁₈NO₄: 204.1236, found: 204.1236.

(R)-methyl 2-((tert-butoxycarbonyl)amino)propanoate (5g, 24.6 mmol, 1 equiv) was dissolved in THF (125 mL, 0.2 M) and cooled to 0 °C. MeMgBr (32.8 mL, 98.4 mmol, 5 equiv, 3.0 M soln in Et₂O) was added slowly and the reaction was allowed to warm to room temperature and stirred overnight. The reaction was then quenched *carefully* with NH₄Cl (sat'd aq) and extracted with EtOAc (3 × 75 mL). The organic layer was dried with Na₂SO₄ and concentrated. The crude oil was purified by silica gel chromatography eluting with Hex/EtOAc (0–75% EtOAc) with the desired product eluting between 30–50% EtOAc. (R)-tert-butyl (3-hydroxy-3-methylbutan-2-yl)carbamate was isolated as a clear oil (3.15 g, 63% yield). [α]_D²⁰ = 1.9 (c = 1.4, CHCl₃); ¹H NMR (400MHz, CDCl₃) δ: 4.82 (1H, d, *J* = 7.2 Hz), 3.54 (1H, bs), 2.58 (1H, bs), 1.41 (9H, s), 1.19 (3H, s), 1.14 (3H, s), 1.09 (3H, d, *J* = 6.8 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 156.3, 79.3, 72.8, 54.5, 28.3, 27.3, 25.6, 16.1; HRMS (ES+, M+H) calcd for C₁₀H₂₂NO₃: 204.1600, found: 204.1598.

(R)-3-Amino-2-methylbutan-2-ol (29)—In a scintillation vial (R)-tert-butyl (3-hydroxy-3-methylbutan-2-yl)carbamate (1 equiv) was dissolved in CH₂Cl₂ (0.1 M) and cooled to 0 °C. Trifluoroacetic acid (0.2M) was added and the reaction mixture was stirred for 1 h. The starting material was determined to be consumed by TLC and the reaction mixture was concentrated resulting in a brown oil. The resulting (R)-3-amino-2-methylbutan-2-ol TFA salt was dissolved in DMF (0.2 M) and used without purification.

(R)-5-Bromo-N-(3-hydroxy-3-methylbutan-2-yl)picolinamide (30)—In a scintillation vial (R)-tert-butyl (3-hydroxy-3-methylbutan-2-yl)carbamate (1.5 g, 7.4 mmol, 1 equiv) was dissolved in CH₂Cl₂ (6 mL, 0.12 M) and cooled to 0 °C. Trifluoroacetic acid (3 mL, 0.25 M) was added and the reaction mixture was stirred for 1 h. The starting material was determined to be consumed by TLC, the reaction mixture was concentrated via rotary evaporation resulting in a brown oil. The resulting (R)-3-amino-2-methylbutan-2-ol TFA salt was dissolved in DMF (5 mL) and used without purification. In a 100 mL round bottom

flask 5-bromopicolinic acid (1.49 g, 7.4 mmol, 1.0 equiv) and HATU (3.1 g, 8.14 mmol, 1.1 equiv) were combined in DMF (25 mL, 0.3 M). *N,N*-Diisopropylethylamine (3.2 mL, 18.25 mmol, 5 equiv) was then added and the reaction was stirred for 15 min. The (*R*)-3-amino-2-methylbutan-2-ol TFA salt was added as a solution in DMF and the reaction was stirred 18 h after which the reaction was determined to be complete by LC/MS. The reaction mixture was partitioned between EtOAc (75 mL) and H₂O (25 mL). After separating the aqueous layer the organic layer was washed again with H₂O (2 × 15 mL). The organic layer was then dried with Na₂SO₄, concentrated, and purified via silica gel chromatography eluting with Hex/EtOAc (0–75% EtOAc) with the aryl bromide eluting at 40% EtOAc. The product was isolated as a brown oil (1.72 g, 81% yield). $[\alpha]_{\text{D}}^{20} = -13.7$ (*c* = 0.81, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 8.51 (1H, bs), 8.09 (1H, d, *J* = 9.2 Hz), 8.01 (1H, m), 7.90 (1H, m), 4.04 (1H, m), 3.03 (1H, bs), 1.22 (9 H, bs); ¹³C NMR (100 MHz, CDCl₃) δ 163.4, 149.1, 148.2, 139.8, 123.7, 123.6, 72.6, 53.5, 27.4, 25.8, 15.7; HRMS (ES⁺, M+Na) calcd for C₁₁H₁₅N₂O₂BrNa: 309.0215, found: 309.0212.

General Methods for Series 31

Method A, 31a–n—In a scintillation vial, (*R*)-5-bromo-*N*-(3-hydroxy-3-methylbutan-2-yl)picolinamide, **31**, (1 equiv) was placed under argon atmosphere, and dissolved in DMF (0.25M). PdCl₂(PPh₃)₂ (0.05 equiv) CuI (0.1 equiv) were added, followed by an alkyne (1.25 equiv) and Et₃NH (6 equiv). The reaction mixture was heated to 90 °C for 45 min after which the reaction was determined to be complete by LC/MS. The reaction mixture was filtered through a Fisherbrand Nylon 0.45 μm syringe filter and purified directly by preparative RP-HPLC eluting with 0.1% TFA in H₂O/ MeCN (10 –90% MeCN).

Method B, 31o–r—In a scintillation vial, (*R*)-5-ethynyl-*N*-(3-hydroxy-3-methylbutan-2-yl)picolinamide, **33**, (1 equiv) was placed under argon atmosphere, and dissolved in DMF (0.25M). An aryl halide (1 equiv), Pd(PPh₃)₄ (0.05 equiv) and CuI (0.1 equiv) added, followed by Et₃N (17 equiv). The reaction mixture heated to 60 °C until the reaction was determined to be complete by LC/MS (1 to 2 h). The reaction mixture was filtered through a Fisherbrand Nylon 0.45 μm syringe filter and purified directly by preparative RP-HPLC eluting with 0.1% TFA in H₂O/ MeCN (10 – 90% MeCN).

(*R*)-5-((3-Fluorophenyl)ethynyl)-*N*-(3-hydroxy-3-methylbutan-2-yl)-3-methylpicolinamide (31d)—LCMS: *t*_R = 0.798 min, >98% at 215 and 254 nm, *m/z* = 341.2 [M + H]⁺. $[\alpha]_{\text{D}}^{20} = -14.2$ (*c* = 0.74, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 8.48 (1H, d, *J* = 1.6 Hz), 8.24 (1H, d, *J* = 8.8 Hz), 7.70 (1H, d, *J* = 1.2 Hz), 7.32 (2H, m), 7.24 (1H, m), 7.10 (1H, m), 4.10 (1H, dq, *J* = 8.9, 6.9 Hz), 2.73 (3H, s), 2.68 (1H, bs), 1.27 (9H, m); ¹³C NMR (100 MHz, CDCl₃) δ 165.6, 162.3 (d, *J*_{C-F} = 245.6 Hz), 147.6, 146.0, 143.0, 135.0, 130.1 (d, *J*_{C-F} = 8.6 Hz), 127.6 (d, *J*_{C-F} = 3.0 Hz), 124.0 (d, *J*_{C-F} = 9.4 Hz), 121.8, 118.5 (d, *J*_{C-F} = 22.8 Hz), 116.4 (d, *J*_{C-F} = 21.1 Hz), 92.8, 86.2, 73.1, 53.4, 27.6, 25.5, 20.3, 16.0; HRMS (ES⁺, M+H) calcd for C₂₀H₂₂FN₂O₂: 341.1665, found: 341.1663.

(*R*)-*N*-(3-Hydroxy-3-methylbutan-2-yl)-5-(pyridin-2-ylethynyl)picolinamide (31i)—LCMS: *t*_R = 0.533 min, >98% at 215 and 254 nm, *m/z* = 310.2 [M + H]⁺. $[\alpha]_{\text{D}}^{20} = -21.1$ (*c* = 0.53, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 8.71 (1H, bs), 8.64 (1H, d, *J* = 4.6 Hz), 8.17 (2H, d, *J* = 8.1 Hz), 7.99 (1H, dd, *J* = 8.1, 1.7 Hz), 7.71 (1H, dt, *J* = 7.8, 1.5 Hz), 7.55 (1H, d, *J* = 7.9 Hz), 7.28 (1H, m), 4.11 (1H, dq, *J* = 8.9, 6.7 Hz), 2.70 (1H, bs), 1.27 (3H, d, *J* = 6.8 Hz), 1.26 (6H, d, *J* = 8.1 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 163.7, 150.7, 150.2, 148.8, 142.4, 140.1, 136.3, 127.4, 123.4, 121.9, 121.7, 93.4, 85.1, 72.9, 53.7, 27.6, 25.8, 15.9; HRMS (ES⁺, M+H) calcd for C₁₈H₂₀N₃O₂: 310.1556, found: 310.1554.

(R)-N-(3-Hydroxy-3-methylbutan-2-yl)-5-(pyridin-4-ylethynyl)picolinamide (31k)

—LCMS: t_R = 0.461 min, >98% at 215 and 254 nm, m/z = 310.2 $[M + H]^+$. $[\alpha]_D^{20}$ = -27.8 (c = 0.48, $CHCl_3$); 1H NMR (400MHz, $CDCl_3$) δ 8.67 (1H, dd, J = 1.6 Hz), 8.65 (1H, bs), 8.20 (1H, m), 8.17 (1H, bs), 7.97 (1H, dd, J = 8.2, 2.0 Hz), 7.41 (2H, d, J = 4.9 Hz), 4.12 (1H, dq, J = 9.5, 7.0 Hz), 2.59 (1H, bs), 1.29 (3H, d, J = 6.9 Hz), 1.28 (6H, d, J = 5.6 Hz); ^{13}C NMR (100 MHz, $CDCl_3$) δ 163.6, 150.6, 149.8, 149.0, 140.1, 130.3, 125.6, 121.7, 91.5, 89.8, 72.9, 53.7, 27.6, 25.8, 15.9; HRMS (ES+, $M+H$) calcd for $C_{18}H_{20}N_3O_2$: 310.1556, found: 310.1554.

(R)-5-Ethynyl-N-(3-hydroxy-3-methylbutan-2-yl)picolinamide (33)—In a 100 mL round bottom flask (R)-5-bromo-N-(3-hydroxy-3-methylbutan-2-yl)picolinamide (1.5 g, 5.2 mmol, 1 equiv), $PdCl_2(PPh_3)_2$ (187 mg, 0.26 mmol, 0.05 equiv), and CuI (99 mg, 0.52 mmol, 0.1 equiv) were combined, placed under argon atmosphere, and dissolved in DMF (15 mL, 0.35M). Trimethylsilylacetylene (1.1 mL, 7.8 mmol, 1.5 equiv) was added, followed by Et_2NH (3.2 mL, 31.2 mmol, 6 equiv). The reaction mixture heated to 90 °C for 45 min after which the reaction was determined to be complete by LC/MS. The reaction mixture was diluted with EtOAc (45 mL) and washed with H_2O (3×15 mL). The organic layer was dried with Na_2SO_4 , concentrated and purified via silica gel chromatography eluting with Hex/EtOAc (0 to 75 % EtOAc) with the trimethylsilyl protected acetylene eluting at 40% EtOAc as a pale yellow oil (1.22 g, 77% yield). 1H NMR (400MHz, $CDCl_3$) δ 8.55 (1H, bs), 8.10 (1H, d, J = 9.1 Hz), 8.14 (1H, dd, J = 8.1, 1.8 Hz), 7.85 (1H, dd, J = 8.1, 2.0 Hz), 4.10 (1H, m), 2.65 (1H, bs), 1.27 (3H, d, J = 7.7 Hz), 1.26 (6H, d, J = 5.8 Hz), 0.26 (9H, s).

The trimethylsilyl protected acetylene (1.22 g, 4.0 mmol, 1 equiv) was dissolved in MeOH/THF (1:1, 16 mL, 0.25 M) and K_2CO_3 (1.1 g, 8.0 mmol, 2 equiv) was added. The reaction was stirred at room temperature for 1h after which it was determined to be complete by LC/MS. The reaction mixture was diluted with H_2O (5 mL) and extracted with EtOAc (3×20 mL). The organic layer was dried with Na_2SO_4 , concentrated and purified via silica gel chromatography eluting with Hex/EtOAc (0 to 100 % EtOAc) with the acetylene eluting at 60 – 80% EtOAc as a pale yellow oil (883 mg, 95% yield). $[\alpha]_D^{20}$ = -4.9 (c = 0.73, $CHCl_3$); 1H NMR (400MHz, $CDCl_3$) δ 8.61 (1H, d, J = 1.2 Hz), 8.17 (1H, bs), 8.14 (1H, dd, J = 8.0, 0.3 Hz), 7.90 (1H, dd, J = 8.1, 2.0 Hz), 4.10 (1H, dq, J = 9.1, 6.9 Hz), 3.34 (1H, s), 2.58 (1H, s), 1.27 (3H, d, J = 6.9 Hz), 1.26 (6H, d, J = 5.8 Hz); ^{13}C NMR (100 MHz, $CDCl_3$) δ 163.7, 151.0, 148.8, 140.4, 121.8, 121.7, 82.7, 79.9, 73.0, 53.7, 27.6, 25.7, 15.9; HRMS (ES+, $M+Na$) calcd for $C_{13}H_{16}N_2O_2Na$: 255.1109, found: 255.1107.

General Methods for Series 36

Method A, 36a–b, d–e, h–j—In a scintillation vial, an aryl halide carboxylic acid, **34a**, (1 equiv), $PdCl_2(PPh_3)_2$ (0.05 equiv), and CuI (0.1 equiv) were combined, placed under argon atmosphere, and dissolved in DMF (0.25M). 3-fluorophenylacetylene (1.25 equiv) was added, followed by Et_2NH (6 equiv). The reaction mixture heated to 90 °C for 45 min after which the reaction was determined to be complete by LC/MS. The reaction mixture was filtered through a Fisherbrand Nylon 0.45 μ m syringe filter and purified directly by preparative RP-HPLC eluting with 0.1% TFA in H_2O / MeCN (10 – 90% MeCN) to yield the desired acetylene carboxylic acid **35a**.

In a scintillation vial acetylene carboxylic acid **35a** (1.0 equiv) and HATU (1.1 equiv) were combined in DMF (0.25 M). *N,N*-Diisopropylethylamine (DIPEA, 5 equiv) was then added. After the reaction mixture was stirred for 10 min a solution of freshly prepared (R)-3-amino-2-methylbutan-2-ol TFA salt in DMF (1.1 equiv) was added and the reaction was stirred until determined to be complete by LC/MS (2 to 20 h). The reaction mixture was

filtered through a Fisherbrand Nylon 0.45 μ m syringe filter and purified directly by preparative RP-HPLC eluting with 0.1% TFA in H₂O/ MeCN (10 – 90% MeCN).

Method B, 36c, f, g—In a scintillation vial an aryl halide carboxylic ester, **34b**, (1 equiv), Pd(PPh₃)₄ (0.05 equiv) and CuI (0.1 equiv) were combined, placed under an argon atmosphere, and dissolved in DMF (0.25 M). 3-fluorophenylacetylene (1.25 equiv) was added, followed by Et₃N (17 equiv). The reaction mixture heated to 60 °C until the reaction was determined to be complete by LC/MS (1 to 2 h). The reaction mixture was filtered through a Fisherbrand Nylon 0.45 μ m syringe filter and purified directly by preparative RP-HPLC eluting with 0.1% TFA in H₂O/ MeCN (10 – 90% MeCN) to yield the desired acetylene carboxylic ester **35b**.

Methyl or ethyl ester **35b** (1 equiv) was dissolved in THF:H₂O (4:1, 0.1 M), and LiOH (3 equiv) was added. The reaction was vigorously stirred until the starting material was observed to be consumed by LC/MS (30 min to 16h). The reaction was quenched with 2 M HCl and extracted with ethyl acetate (3 $\times$ 10 mL). The organic layers were combined, dried with Na₂SO₄, concentrated, and used without further purification. In a scintillation vial the resulting acetylene carboxylic acid (1.0 equiv) and HATU (1.1 equiv) were combined in DMF (0.25 M). *N,N*-Diisopropylethylamine (DIPEA, 5 equiv) was then added. After the reaction mixture was stirred for 10 min a solution of freshly prepared (*R*)-3-amino-2-methylbutan-2-ol TFA salt in DMF (1.1 equiv) was added and the reaction was stirred until determined to be complete by LC/MS (2 to 20 h). The reaction mixture was filtered through a Fisherbrand Nylon 0.45 μ m syringe filter and purified directly by preparative RP-HPLC eluting with 0.1% TFA in H₂O/ MeCN (10 – 90% MeCN).

(*R*)-6-((3-Fluorophenyl)ethynyl)-*N*-(3-hydroxy-3-methylbutan-2-yl)nicotinamide (36b)—LCMS: t_R = 0.765 min, >98% at 215 and 254 nm, m/z = 326. 9 [M + H]⁺. [α]_D²⁰ = -7.5 (c = 0.57, CHCl₃); ¹H NMR (400MHz, CDCl₃) δ 8.98 (1H, d, J = 1.8 Hz), 8.10 (1H, dd, J = 8.1, 2.3 Hz), 7.55 (1H, d, J = Hz), 7.32 (3H, m), 7.08 (1H, m), 6.76 (1H, d, J = 8.8 Hz), 4.13 (1H, dq, J = 8.8, 6.8 Hz), 2.62 (1H, bs), 1.29 (6H, d, J = 4.4 Hz), 1.27 (3H, d, J = 6.8 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 164.8, 162.3, (d, J_{C-F} = 245 Hz), 148.3, 145.3, 135.3, 130.1 (d, J_{C-F} = 8.5 Hz), 129.1, 128.0 (d, J_{C-F} = 7.0 Hz), 126.9, 123.5 (d, J_{C-F} = 9.4 Hz), 118.8 (d, J_{C-F} = 23.0), 116.8 (d, J_{C-F} = 21.0 Hz), 90.0 (d, J_{C-F} = 3.4 Hz), 88.7, 72.6, 53.7, 28.0, 26.3, 15.7; HRMS (ES⁺, M+H) calcd for C₁₉H₂₀FN₂O₂: 327.1509, found: 327.1510.

(*R*)-6-((3-Fluorophenyl)ethynyl)-*N*-(3-hydroxy-3-methylbutan-2-yl)-5-methylnicotinamide (36e)—LCMS: t_R = 0.816 min, >98% at 215 and 254 nm, m/z = 341.2 [M + H]⁺. [α]_D²⁰ = -17.9 (c = 0.43, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 8.57 (1H, s), 8.17 (1H, d, J = 7.2 Hz), 8.07 (1H, s), 7.36 (2H, s), 7.24 (1H, m), 7.09 (1H, m), 4.12 (1H, dq, J = 8.9, 6.9 Hz), 2.55 (3H, s), 1.71 (1H, bs), 1.29 (3H, d, J = 6.8 Hz), 1.28 (6H, d, J = 9.0 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 164.2, ((d, J_{C-F} = 245.7 Hz), 150.6, 150.5, 148.2, 130.1 (d, J_{C-F} = 8.6 Hz), 127.6 (d, J_{C-F} = 3.0 Hz), 124.2 (d, J_{C-F} = 9.2 Hz), 122.9, 122.6, 118.6 (d, J_{C-F} = 22.7 Hz), 116.4 (d, J_{C-F} = 21.1 Hz), 96.8, 85.4, 73.1, 53.8, 27.6, 25.6, 20.4, 15.9; HRMS (ES⁺, M+H) calcd for C₂₀H₂₂FN₂O₂: 341.1665, found: 341.1664.

(*R*)-2-((3-Fluorophenyl)ethynyl)-*N*-(3-hydroxy-3-methylbutan-2-yl)pyrimidine-5-carboxamide (36f)—LCMS: t_R = 0.708 min, >98% at 215 and 254 nm, m/z = 327.9 [M + H]⁺. [α]_D²⁰ = -8.9 (c = 0.67, CHCl₃); ¹H NMR (400MHz, CDCl₃) δ 9.12 (2H, s), 7.43 (1H, d, J = 7.8 Hz), 7.34 (2H, m), 7.14 (1H, td, J = 9.2, 2.4 Hz), 6.75 (1H, d, J = 8.8 Hz), 4.14 (1H, dq, J = 8.8, 6.9 Hz), 2.31 (1H, bs), 1.30 (6H, s), 1.28 (3H, d, J = 6.9 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 162.8, 162.2 (d, J_{C-F} = 246.1 Hz), 156.1, 154.3, 130.2 (d, J_{C-F} = 8.4

(Hz), 128.6 (d, $J_{\text{C-F}} = 3.1$ Hz), 125.9, 122.6 (d, $J_{\text{C-F}} = 9.4$ Hz), 119.4 (d, $J_{\text{C-F}} = 23.1$ Hz), 117.5 (d, $J_{\text{C-F}} = 21.2$ Hz), 88.6 (d, $J_{\text{C-F}} = 3.5$ Hz), 88.2, 72.5, 53.7, 28.0, 26.4, 15.7; HRMS (ES⁺, M+H) calcd for C₁₈H₁₉FN₃O₂: 328.1461, found: 328.1459.

5-((3-Fluorophenyl)ethynyl)-N-(3-hydroxy-3-methylbutyl)picolinamide (38p)—

LCMS: $t_{\text{R}} = 0.870$ min, >98% at 215 and 254 nm, $m/z = 326.9$ [M + H]⁺. ¹H NMR (400MHz, CDCl₃) δ 8.61 (1H, bs), 8.42 (1H, m), 8.15 (1H, d, $J = 8.1$ Hz), 7.90 (1H, dd, $J = 8.1, 2.0$ Hz), 7.31 (2H, m), 7.22 (1H, m), 7.07 (1H, m), 3.63 (2H, q, $J = 6.1$ Hz), 2.44 (1H, bs), 1.82 (2H, t, $J = 7.0$ Hz), 1.30 (6H, s); ¹³C NMR (100 MHz, CDCl₃) δ 163.8, 162.3, (d, $J_{\text{C-F}} = 245.7$ Hz), 150.4, 148.7, 139.7, 130.1 (d, $J_{\text{C-F}} = 8.6$ Hz), 127.6 (d, $J_{\text{C-F}} = 3.1$ Hz), 123.9 (d, $J_{\text{C-F}} = 9.4$ Hz), 122.7, 121.5, 118.5 (d, $J_{\text{C-F}} = 22.8$ Hz), 116.4 (d, $J_{\text{C-F}} = 21.1$ Hz), 93.1 (d, $J_{\text{C-F}} = 3.5$ Hz), 86.3, 70.5, 42.0, 35.8, 29.6; HRMS (ES⁺, M+H) calcd for C₁₉H₂₀FN₂O₂: 327.1509, found: 327.1508.

(R)-5-((3-Fluorophenyl)ethynyl)-N-(1,1,1-trifluoropropan-2-yl)picolinamide (38r)

—LCMS: $t_{\text{R}} = 1.030$ min, >98% at 215 and 254 nm, $m/z = 336.9$ [M + H]⁺. [α]_D²⁰ = 10.5 (c = 0.59, CHCl₃); ¹H NMR (400MHz, CDCl₃) δ 8.68 (1H, d, $J = 1.4$ Hz), 8.20 (1H, d, $J = 8.1$ Hz), 8.11 (1H, d, $J = 9.8$ Hz), 7.97 (1H, dd, $J = 7.8, 1.8$ Hz), 7.35 (2H, m), 7.27 (1H, m), 7.10 (1H, m), 4.88 (1H, m), 1.46 (3H, d, $J = 7.0$ Hz); ¹³C NMR (100 MHz, CDCl₃) δ 163.3, 162.4 (d, $J_{\text{C-F}} = 245.7$ Hz), 150.5, 147.4, 139.9, 130.2 (d, $J_{\text{C-F}} = 8.6$ Hz), 127.7 (d, $J_{\text{C-F}} = 3.1$ Hz), 125.3 (q, $J_{\text{C-F}} = 279.3$ Hz), 123.8 (d, $J_{\text{C-F}} = 9.4$ Hz), 123.2, 122.0, 118.6 (d, $J_{\text{C-F}} = 22.9$ Hz), 116.6 (d, $J_{\text{C-F}} = 21.0$ Hz), 93.7, 86.1, 46.5 (q, $J_{\text{C-F}} = 31.6$ Hz), 14.4 (d, $J_{\text{C-F}} = 1.5$ Hz); HRMS (ES⁺, M+H) calcd for C₁₇H₁₃F₄N₂O: 337.0964, found: 337.0966.

(S)-5-((3-Fluorophenyl)ethynyl)-N-(1,1,1-trifluoropropan-2-yl)picolinamide (38s)

—LCMS: $t_{\text{R}} = 1.030$ min, >98% at 215 and 254 nm, $m/z = 336.9$ [M + H]⁺. [α]_D²⁰ = -10.0 (c = 0.82, CHCl₃); ¹H NMR (400MHz, CDCl₃) δ 8.68 (1H, d, $J = 1.4$ Hz), 8.20 (1H, d, $J = 8.1$ Hz), 8.11 (1H, d, $J = 9.8$ Hz), 7.97 (1H, dd, $J = 7.8, 1.8$ Hz), 7.35 (2H, m), 7.27 (1H, m), 7.10 (1H, m), 4.88 (1H, m), 1.46 (3H, d, $J = 7.0$ Hz); ¹³C NMR (100 MHz, CDCl₃) δ 163.3, 162.4 (d, $J_{\text{C-F}} = 245.7$ Hz), 150.5, 147.4, 139.9, 130.2 (d, $J_{\text{C-F}} = 8.6$ Hz), 127.7 (d, $J_{\text{C-F}} = 3.1$ Hz), 125.3 (q, $J_{\text{C-F}} = 279.3$ Hz), 123.8 (d, $J_{\text{C-F}} = 9.4$ Hz), 123.2, 122.0, 118.6 (d, $J_{\text{C-F}} = 22.9$ Hz), 116.6 (d, $J_{\text{C-F}} = 21.0$ Hz), 93.7, 86.1, 46.5 (q, $J_{\text{C-F}} = 31.6$ Hz), 14.4 (d, $J_{\text{C-F}} = 1.5$ Hz); HRMS (ES⁺, M+H) calcd for C₁₇H₁₃F₄N₂O: 337.0964, found: 337.0963.

5-((3-Fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinamide (38t)—

LCMS: $t_{\text{R}} = 0.879$ min, >98% at 215 and 254 nm, $m/z = 310.9$ [M + H]⁺. ¹H NMR (400MHz, CDCl₃) δ 8.64 (1H, d, $J = 1.4$ Hz), 8.29 (1H, bs), 8.13 (1H, d, $J = 7.8$ Hz), 7.93 (1H, dd, $J = 8.1, 2.0$ Hz), 7.33 (2H, m), 7.24 (1H, m), 7.09 (1H, m), 4.94 (2H, d, $J = 6.4$ Hz), 4.57 (2H, d, $J = 6.5$ Hz), 1.77 (3H, s); ¹³C NMR (100 MHz, CDCl₃) δ 162.9, 162.3 (d, $J_{\text{C-F}} = 245.9$ Hz), 150.4, 148.2, 139.8, 130.1 (d, $J_{\text{C-F}} = 8.6$ Hz), 127.6 (d, $J_{\text{C-F}} = 3.0$ Hz), 123.8 (d, $J_{\text{C-F}} = 9.3$ Hz), 122.7, 121.3, 118.5 (d, $J_{\text{C-F}} = 22.9$ Hz), 116.5 (d, $J_{\text{C-F}} = 21.0$ Hz), 93.5 (d, $J_{\text{C-F}} = 3.5$ Hz), 86.2, 81.8, 53.6, 23.6; HRMS (ES⁺, M+H) calcd for C₁₈H₁₆FN₂O₂: 311.1196, found: 311.1197.

5-((3-Fluorophenyl)ethynyl)-N-((3-methyloxetan-3-yl)methyl)picolinamide (38u)

—LCMS: $t_{\text{R}} = 0.797$ min, >98% at 215 and 254 nm, $m/z = 325.1$ [M + H]⁺. ¹H NMR (400MHz, CDCl₃) δ 8.67 (1H, d, $J = 1.3$ Hz), 8.29 (1H, bs), 8.20 (1H, d, $J = 7.6$ Hz), 7.97 (1H, dd, $J = 6.0, 2.0$ Hz), 7.35 (2H, m), 7.26 (1H, m), 7.10 (1H, m), 4.59 (2H, d, $J = 6.0$ Hz), 4.44 (2H, d, $J = 6.0$ Hz), 3.68 (2H, d, $J = 6.5$ Hz), 1.40 (3H, s); ¹³C NMR (100 MHz, CDCl₃) δ 164.2, 162.4 (d, $J_{\text{C-F}} = 245.9$ Hz), 150.5, 148.2, 139.9, 130.2 (d, $J_{\text{C-F}} = 8.7$ Hz), 127.7 (d, $J_{\text{C-F}} = 3.0$ Hz), 123.9 (d, $J_{\text{C-F}} = 9.4$ Hz), 122.7, 121.8, 118.6 (d, $J_{\text{C-F}} = 22.8$ Hz),

116.6 (d, J_{C-F} = 21.1 Hz), 93.4 (d, J_{C-F} = 3.7 Hz), 86.3, 80.3, 45.9, 40.2, 22.0; HRMS (ES+, M+H) calcd for $C_{19}H_{18}FN_2O_2$: 325.1352, found: 325.1353.

5-((3-Fluorophenyl)ethynyl)picolinic acid (37)—In a 100 mL round bottom flask 5-bromopicolinic acid (3g, 14.8 mmol, 1 equiv), $PdCl_2(PPh_3)_2$ (519 mg, 0.74 mmol, 0.05 equiv), and CuI (282 mg, 1.48 mmol, 0.1 equiv) were combined, place under an argon atmosphere and dissolved in DMF (50 mL, 0.3M). 3-Fluorophenylacetylene (2.05 mL, 17.76 mmol, 1.2 equiv) was added, followed by Et_2NH (9.2 mL, 88.8 mmol, 6 equiv). The reaction mixture heated to 90 °C for 45 min after which the reaction was determined to be complete by LC/MS. The crude reaction mixture was diluted with EtOAc (50 mL) and H_2O (50 mL). After separating the organic layer, the aqueous layer was washed with EtOAc (2 × 25 mL). The aqueous layer was then acidified to ~ pH = 2 with 2M HCl, and extracted with EtOAc (3 × 50 mL). The organic layer was dried with Na_2SO_4 , concentrated, and used without further purification. The product was isolated as a white solid (2.32 g, 65%). 1H NMR (400MHz, CD_3OD) δ 8.84 (1H, bs), 8.16 (2H, m), 7.44 (2H, m), 7.34 (1H, d, J = 9.7 Hz), 7.21 (1H, m); ^{13}C NMR (100 MHz, CD_3OD) δ 167.0, 163.9, (d, J_{C-F} = 244.4 Hz), 152.5, 148.0, 141.3, 131.7 (d, J_{C-F} = 8.6 Hz), 129.0, 125.8, 125.2 (d, J_{C-F} = 9.3 Hz), 124.8, 119.4 (d, J_{C-F} = 23.4 Hz), 117.7 (d, J_{C-F} = 21.4 Hz), 94.8, 86.8; HRMS (ES+, M+H) calcd for $C_{14}H_9FNO_2$: 242.0617, found: 242.0618.

Amide Analogs 19, 38a–d, g–v—In a scintillation vial 5-((3-fluorophenyl)ethynyl)picolinic acid, **37**, (1.0 equiv) and HATU (1.1 equiv) were combined in DMF (0.25 M). *N,N*-Diisopropylethylamine (DIPEA, 3 equiv) was then added. The reaction mixture was stirred for 10 min after which an amine (1.1 equiv) was added. The reaction was stirred until determined to be complete by LC/MS (2 to 20 h). The reaction mixture was filtered through a Fisherbrand Nylon 0.45 μ m syringe filter and purified directly by preparative RP-HPLC eluting with 0.1% TFA in H_2O / MeCN (10 – 90% MeCN).

(R)-5-((3-Fluorophenyl)ethynyl)-N-(3-hydroxy-3-methylbutan-2-yl)picolinamide (19)—LCMS: t_R = 0.731 min, >98% at 215 and 254 nm, m/z = 327.1 $[M + H]^+$. $[\alpha]_D^{20}$ = –22.2 (c = 0.43, $CHCl_3$); 1H NMR (400MHz, $CDCl_3$) δ 8.65 (1H, dd, J = 1.3, 0.7 Hz), 8.19 (2H, dd, J = 8.1, 0.7 Hz), 7.95 (1H, dd, J = 8.1, 2.0 Hz), 7.34 (2H, m), 7.24 (1H, m), 7.09 (1H, m), 4.13 (1H, dq, J = 9.1, 6.8 Hz), 2.50 (1H, bs), 1.29 (3H, d, J = 6.8 Hz), 1.28 (6H, d, J = 8.0 Hz); ^{13}C NMR (100 MHz, $CDCl_3$) δ 163.8, 162.3 (d, J_{C-F} = 245.7 Hz), 150.4, 148.4, 139.8, 130.1 (d, J_{C-F} = 8.6 Hz), 127.7 (d, J_{C-F} = 3.0 Hz), 123.9 (d, J_{C-F} = 9.3 Hz), 122.5, 121.8, 118.5 (d, J_{C-F} = 22.9 Hz), 116.5 (d, J_{C-F} = 21.0 Hz), 93.3, 86.3, 73.1, 53.8, 27.6, 25.7, 15.9; HRMS (ES+, M+H) calcd for $C_{19}H_{20}FN_2O_2$: 327.1509, found: 327.1507.

(R)-N-(3-Fluoro-3-methylbutan-2-yl)-5-((3-fluorophenyl)ethynyl)picolinamide (38e)—(R)-5-((3-fluorophenyl)ethynyl)-N-(3-hydroxy-3-methylbutan-2-yl)picolinamide, **19** (40 mg, 0.12 mmol, 1.0 equiv) was dissolved in CH_2Cl_2 (1.2 mL, 0.1 M) and cooled to –78 °C. DAST (19 μ L, 0.12 mmol, 1.0 equiv) was added dropwise and the reaction was allowed to slowly warm to rt over 4 h. The reaction was determined to be complete by LC/MS and was quenched carefully by the addition of H_2O (0.5 mL). The aqueous layer was extracted with EtOAc (3 × 5 mL), dried Na_2SO_4 , concentrated and purified by preparative RP-HPLC eluting with 0.1% TFA in H_2O / MeCN (10 – 90% MeCN) to afford the title compound in 30% yield. LCMS: t_R = 0.926 min, >98% at 215 and 254 nm, m/z = 329.1 $[M + H]^+$. $[\alpha]_D^{20}$ = –5.9 (c = 1.16, $CHCl_3$); 1H NMR (400MHz, $CDCl_3$) δ 8.68 (1H, d, J = 1.3 Hz), 8.19 (1H, dd, J = 12.0, 0.4 Hz), 8.14 (1H, d, J = 9.8 Hz), 7.96 (1H, dd, J = 8.1, 2.0 Hz), 7.35 (2H, m), 7.27 (1H, m), 7.10 (1H, m), 4.29 (1H, m), 1.57 (1H, bs), 1.46 (3H, d, J = 16.7 Hz), 1.40 (3H, d, J = 16.7 Hz), 1.33 (3H, d, J = 6.9 Hz); ^{13}C NMR (100 MHz, $CDCl_3$) δ 163.2, 162.4 (d, J_{C-F} = 22.9 Hz), 150.5, 148.4, 139.8, 130.1 (d, J_{C-F} = 8.7 Hz), 127.7 (d, J_{C-F} = 3.2 Hz),

124.0 (d, $J_{\text{C-F}} = 9.4$ Hz), 122.6, 121.8, 118.6 (d, $J_{\text{C-F}} = 21.8$ Hz), 116.5, (d, $J_{\text{C-F}} = 21.0$ Hz), 96.6 (d, $J_{\text{C-F}} = 170.7$ Hz), 93.3 (d, $J_{\text{C-F}} = 3.4$ Hz), 86.4, 51.8 (d, $J_{\text{C-F}} = 22.2$ Hz), 24.6 (d, $J_{\text{C-F}} = 7.8$ Hz), 24.3 (d, $J_{\text{C-F}} = 7.4$ Hz), 15.6 (d, $J_{\text{C-F}} = 3.7$ Hz); HRMS (ES⁺, M+H) calcd for C₁₉H₁₈F₂N₂ONa: 351.1285, found: 351.1282.

(R)-5-((3-Fluorophenyl)ethynyl)-N-(3-methoxy-3-methylbutan-2-yl)picolinamide (38f)—(R)-5-((3-fluorophenyl)ethynyl)-N-(3-hydroxy-3-methylbutan-2-yl)picolinamide, **19**

(68 mg, 0.21 mmol, 1.0 equiv) was dissolved in THF (2 mL, 0.1 M) and cooled to 0 °C. NaH (11.1 mg, 0.46 mmol, 2.2 equiv) was added. The reaction mixture was warmed to rt and stirred for 10 min. Methyl iodide (15 μ L, 0.23 mmol, 1.1 equiv) was added and the reaction mixture was stirred at room temperature overnight. Analysis of the reaction mixture by LC/MS revealed ~70% of the desired product, ~20% starting material, and ~10% dimethylated product. The reaction was quenched with NH₄Cl (sat'd, aq) and extracted with EtOAc (3 $\times$ 5 mL). The organic layers were dried with Na₂SO₄, concentrated and purified by preparative RP-HPLC eluting with 0.1% TFA in H₂O/ MeCN (10 – 90% MeCN) to afford the product in 58% yield. LCMS: t_R = 0.824 min, >98% at 215 and 254 nm, m/z = 341.2 [M + H]⁺. $[\alpha]_D^{20} = -31.7$ (c = 0.65, CHCl₃); ¹H NMR (400MHz, CDCl₃) δ 8.66 (1H, d, $J = 1.6$ Hz), 8.21 (1H, d, $J = 9.6$ Hz), 8.17 (1H, d, $J = 8.1$ Hz), 7.92 (1H, dd, $J = 8.1, 1.9$ Hz), 7.32 (2H, m), 7.23, (1H, m), 7.07 (1H, m), 4.18 (dq, 1H, $J = 9.5, 6.7$ Hz), 3.25 (3H, s), 1.23 (3H, d, $J = 6.9$ Hz), 1.20 (6H, d, $J = 11.6$ Hz); ¹³C NMR (100 MHz, CDCl₃) δ 163.0, 162.3 (d, $J_{\text{C-F}} = 245.6$ Hz), 150.4, 148.8, 139.6, 130.1 (d, $J_{\text{C-F}} = 8.6$ Hz), 127.6 (d, $J_{\text{C-F}} = 3.0$ Hz), 124.0 (d, $J_{\text{C-F}} = 9.3$ Hz), 122.2, 121.6, 118.5 (d, $J_{\text{C-F}} = 22.9$ Hz), 116.4 (d, $J_{\text{C-F}} = 21.1$ Hz), 93.0, 86.4, 75.9, 52.3, 49.4, 22.0, 21.9, 15.5; HRMS (ES⁺, M+H) calcd for C₂₀H₂₂FN₂O₂: 341.1665, found: 341.1664.

(S)-5-((3-Fluorophenyl)ethynyl)-N-(3-hydroxy-3-methylbutan-2-yl)picolinamide (38i)—

LCMS: t_R = 0.738 min, >98% at 215 and 254 nm, m/z = 327.1 [M + H]⁺. $[\alpha]_D^{20} = 24.3$ (c = 0.48, CHCl₃); ¹H NMR (400MHz, CDCl₃) δ 8.64 (1H, dd, $J = 1.3, 0.7$ Hz), 8.19 (1H, bs), 8.18 (1H, dd, $J = 8.1, 0.7$ Hz), 7.94 (1H, dd, $J = 8.1, 2.0$ Hz), 7.34 (2H, m), 7.24 (1H, m), 7.09 (1H, m), 4.13 (1H, dq, $J = 9.1, 6.8$ Hz), 2.66 (1H, bs), 1.29 (3H, d, $J = 6.8$ Hz), 1.28 (6H, d, $J = 8.0$ Hz); ¹³C NMR (100 MHz, CDCl₃) δ 163.8 162.3 (d, $J_{\text{C-F}} = 245.7$ Hz), 150.4, 148.4, 139.8, 130.1 (d, $J_{\text{C-F}} = 8.6$ Hz), 127.6 (d, $J_{\text{C-F}} = 3.0$ Hz), 123.9 (d, $J_{\text{C-F}} = 9.3$ Hz), 122.5, 121.8, 118.5 (d, $J_{\text{C-F}} = 22.9$ Hz), 116.5 (d, $J_{\text{C-F}} = 21.0$ Hz), 93.3, 86.3, 73.1, 53.7, 27.6, 25.7, 15.9; HRMS (ES⁺, M+H) calcd for C₁₉H₂₀FN₂O₂: 327.1509, found: 327.1507.

General Amide Coupling and Sonogashira Two-step Procedure (44a,b,d, 45)

In a scintillation vial 5-bromopicolinic acid (1.0 equiv) and HATU (1.1 equiv) were combined in DMF (0.25 M). *N,N*-Diisopropylethylamine (DIPEA, 5 equiv) was then added. After the reaction mixture was stirred for 10 min the desired amine was added and the reaction was stirred until determined to be complete by LC/MS (2 to 20 h). The reaction mixture was filtered through a Fisherbrand Nylon 0.45 μ m syringe filter and purified directly by preparative RP-HPLC eluting with 0.1% TFA in H₂O/ MeCN (10 – 90% MeCN).

In a scintillation vial, the aryl bromide (1 equiv), PdCl₂(PPh₃)₂ (0.05 equiv), and CuI (0.1 equiv) were combined, placed under argon atmosphere, and dissolved in DMF (0.25M). The desired ethynylpyridine (2- or 4-ethynylpyridine) (1.25 equiv) was added, followed by Et₂NH (6 equiv). The reaction mixture heated to 90 °C for 45 min after which the reaction was determined to be complete by LC/MS. The reaction mixture was filtered through a Fisherbrand Nylon 0.45 μ m syringe filter and purified directly by preparative RP-HPLC eluting with 0.1% TFA in H₂O/ MeCN (10 – 90% MeCN) to yield products **44a-d** and **45**.

(R)-N-(3-Methylbutan-2-yl)-5-(pyridin-2-ylethynyl)picolinamide (44b)—LCMS: t_R = 0.727 min, >98% at 215 and 254 nm, m/z = 294.2 $[M + H]^+$. $[\alpha]_D^{20}$ = -50.0 (c = 0.78, $CHCl_3$); 1H NMR (400MHz, $CDCl_3$) δ 8.72 (1H, d, J = 1.7 Hz), 8.65 (1H, d, J = 4.7 Hz), 8.20 (1H, d, J = 8.1 Hz), 8.00 (1H, dd, J = 6.1, 2.0 Hz), 7.89 (1H, d, J = 9.0 Hz), 7.73 (1H, dt, J = 7.7, 1.6 Hz), 7.57 (1H, d, J = 7.8 Hz), 7.30 (1H, m), 4.05 (1H, m), 1.84 (1H, sep, J = 6.5 Hz), 1.21 (3H, d, J = 6.7 Hz), 0.97 (6H, dd, J = 6.8, 4.0 Hz); ^{13}C NMR (100 MHz, $CDCl_3$) δ 162.8, 15.07, 150.2, 149.1, 142.4, 140.1, 136.3, 127.4, 123.4, 121.7, 121.6, 93.3, 85.1, 50.2, 33.1, 18.6, 18.5, 17.6; HRMS (ES+, M+H) calcd for $C_{18}H_{20}N_3O$: 294.1606, found: 294.1607.

(R)-N-(3-Fluoro-3-methylbutan-2-yl)-5-(pyridin-2-ylethynyl)picolinamide (44c)—(R)-N-(3-hydroxy-3-methylbutan-2-yl)-5-(pyridin-2-ylethynyl)picolinamide, **31i** (39 mg, 0.12 mmol, 1.0 equiv) was dissolved in CH_2Cl_2 (1.2 mL, 0.1 M) and cooled to -78 °C. DAST (19 μ L, 0.12 mmol, 1.0 equiv) was added dropwise and the reaction was allowed to slowly warm to rt over 4 h. The reaction was determined to be complete by LC/MS and was quenched carefully by the addition of H_2O (0.5 mL). The aqueous layer was extracted with EtOAc (3 $\times$ 5 mL), dried Na_2SO_4 , concentrated and purified by preparative RP-HPLC eluting with 0.1% TFA in H_2O / MeCN (10 – 90% MeCN) to afford the title compound in 81% yield. LCMS: t_R = 0.671 min, >98% at 215 and 254 nm, m/z = 312.2 $[M + H]^+$. $[\alpha]_D^{20}$ = -14.0 (c = 0.46, $CHCl_3$); 1H NMR (400MHz, $CDCl_3$) δ 8.75 (1H, dd, J = 1.9, 0.6 Hz), 8.67 (1H, d, J = 4.0 Hz), 8.20 (1H, dd, J = 8.1, 0.6 Hz), 8.15 (1H, d, J = 9.8 Hz), 8.02 (1H, dd, J = 8.1, 2.0 Hz), 7.74 (1H, dt, J = 7.8, 1.8 Hz), 7.58 (1H, d, J = 7.8 Hz), 7.31 (1H, m), 4.28 (1H, m), 1.45 (3H, d, J = 16.2 Hz), 1.45 (3H, d, J = 16.4 Hz), 1.45 (3H, d, J = 6.9 Hz); ^{13}C NMR (100 MHz, $CDCl_3$) δ 163.0, 150.8, 150.3, 148.7, 142.4, 140.1, 136.3, 127.4, 123.5, 122.0, 121.7, 96.5 (d, J_{C-F} = 170.8 Hz), 93.5, 84.8, 51.4 (d, J_{C-F} = 22.3 Hz), 24.5 (d, J_{C-F} = 5.8 Hz), 24.2 (d, J_{C-F} = 5.3 Hz), 15.5 (d, J_{C-F} = 3.8 Hz); HRMS (ES+, M+H) calcd for $C_{18}H_{19}FN_3O$: 312.1512, found: 312.1511.

N-(3-Methyloxetan-3-yl)-5-(pyridin-2-ylethynyl)picolinamide (44d)—LCMS: t_R = 0.453 min, >98% at 215 and 254 nm, m/z = 294.2 $[M + H]^+$. 1H NMR (400MHz, $CDCl_3$) δ 8.72 (1H, d, J = 1.2 Hz), 8.66 (1H, d, J = 4.4 Hz), 8.28 (1H, bs), 8.15 (1H, d, J = 8.1 Hz), 8.02 (1H, dd, J = 9.2, 3.0 Hz), 7.73 (1H, td, J = 7.8, 1.6 Hz), 7.58 (1H, d, J = 7.8 Hz), 7.31 (1H, m), 4.94 (2H, d, J = 6.3 Hz), 4.58 (2H, d, J = 6.5 Hz), 1.77 (3H, s); ^{13}C NMR (100 MHz, $CDCl_3$) δ 162.9, 150.8, 150.3, 148.6, 142.4, 140.3, 136.4, 127.4, 123.6, 122.4, 121.4, 93.7, 84.9, 81.9, 53.7, 23.7; HRMS (ES+, M+H) calcd for $C_{17}H_{16}N_3O_2$: 294.1243, found: 294.1240.

N-(3-Methyloxetan-3-yl)-5-(pyridin-4-ylethynyl)picolinamide (45)—LCMS: t_R = 0.354 min, >98% at 215 and 254 nm, m/z = 294.2 $[M + H]^+$. 1H NMR (400MHz, $CDCl_3$) δ 8.67 (1H, d, J = 1.2 Hz), 8.65 (2H, m), 8.29 (1H, bs), 8.16 (1H, d, J = 8.1 Hz), 7.98 (1H, dd, J = 8.1, 1.9 Hz), 7.41 (2H, d, J = 5.6 Hz), 4.93 (2H, d, J = 6.4 Hz), 4.58 (2H, d, J = 6.4 Hz), 1.77 (3H, s); ^{13}C NMR (100 MHz, $CDCl_3$) δ 162.9, 150.5, 149.9, 148.8, 140.1, 130.2, 125.5, 122.0, 121.4, 91.7, 89.5, 81.8, 53.7, 23.6; HRMS (ES+, M+H) calcd for $C_{17}H_{16}N_3O_2$: 294.1243, found: 294.1242.

Fluorescence-Based Calcium Flux Assay (Concentration-response curve (potency) and glutamate fold shift (efficacy))

For measurement of compound-evoked increases in intracellular calcium, HEK293 cells stably expressing rat mGlu₅ were plated in 384-well,⁴⁴ poly-D-lysine coated, black-walled, clear-bottomed plates in 20 μ L of assay medium (DMEM supplemented with 10% dialyzed fetal bovine serum, 20 mM HEPES and 1 mM sodium pyruvate) at a density of 15,000 cells/well. Cells were grown overnight at 37°C/5% CO_2 . The next day, medium was removed

from the cells and they were incubated with 20 μ l/well of 1 00B5;M Fluo-4AM (Invitrogen, Carlsbad, California) prepared as a 2.3 mM stock in dimethyl sulfoxide (DMSO) and mixed in a 1:1 ratio with 10% (w/v) pluronic acid F-127 and diluted in calcium assay buffer (Hank's Balanced Salt Solution (HBSS; Invitrogen, Carlsbad, CA) supplemented with 20 mM HEPES and 2.5 mM probenecid, pH 7.4) for 50 min at 37°C. Dye loading solution was removed and replaced with 20 μ l/well of assay buffer. For PAM potency curves, mGlu₅ compounds were diluted in calcium assay buffer and added to the cells followed by the addition of an EC₂₀ concentration of glutamate 140 sec later, and then an EC₈₀ concentration of glutamate 60 sec later. For fold-shift experiments either a single concentration (10 μ M) or multiple fixed concentrations (50 nM - 30 μ M) of mGlu₅ compound or vehicle were added followed by the addition of a concentration-response curve (CRC) of glutamate 140 seconds later. Calcium flux was measured over time as an increase in fluorescence using a Functional Drug Screening System 6000 (FDSS 6000, Hamamatsu, Japan). The change in relative fluorescence over basal was calculated before normalization to the maximal response to glutamate.

Selectivity Screening

mGlu₁—To assess the effect of test compounds at mGlu₁, Ca²⁺ mobilization assays were performed as described previously (Hammond et al., 2010; Noetzel et al., 2012). Briefly HEK293 cells stably expressing rat mGlu₁ were plated in black-walled, clear-bottomed, poly-D-lysine coated 384-well plates (Greiner Bio-One, Monroe, NC) in assay medium at a density of 20,000 cells/well. Calcium flux was measured over time as an increase in fluorescence of the Ca²⁺ indicator dye, Fluo-4AM using a FDSS 6000. Either vehicle or a fixed concentration of test compound (10 μ M, final concentration) was added followed 140 sec later by a CRC of glutamate. Data were analyzed as described above.

Group II and Group III mGlu—The functional activity of the compounds of interest was assessed at the rat group II and III mGlu receptors by measuring thallium flux through GIRK channels as previously described (Niswender et al., 2008). Briefly, HEK293-GIRK cells expressing mGlu subtypes 2, 3, 4, 6, 7 or 8 were plated into 384-well, black-walled, clear-bottom poly-D-lysine coated plates at a density of 15,000 cells/well in assay medium. A single concentration of test compound (10 μ M) or vehicle was added followed 140 sec later by a CRC of glutamate (or L-AP4 for mGlu₇) diluted in thallium buffer (125 mM NaHCO₃, 1 mM MgSO₄, 1.8 mM CaSO₄, 5 mM glucose, 12 mM thallium sulfate, 10 mM HEPES) and fluorescence was measured using a FDSS 6000. Data were analyzed as described previously (Niswender et al., 2008).

Radioligand binding

Membranes were prepared from HEK293A cells expressing rat mGlu₅. Cells were harvested and pelleted by centrifugation and re-suspended in ice-cold homogenization buffer (50 mM Tris-HCl, 10 mM EDTA, 0.9% NaCl, pH7.4), and homogenized by 3 $\times$ 10 sec bursts. Cell fractions were separated by centrifugation and the resulting pellet resuspended in ice-cold assay buffer (50 mM Tris-HCl, 0.9% NaCl, pH7.4). For inhibition binding experiments, membranes (50 Yg/well) were incubated with 7 nM [³H]methoxyPEPy and a range of concentrations of test ligand for 1 h at room temperature with shaking in assay buffer. 10 μ M MPEP was used to determine non-specific binding. Assays were terminated by rapid filtration using a Brandel 96-well plate Harvester, and washed three times with ice-cold assay buffer. The next day MicroScint20 was added and radioactivity was counted.

Electrophysiology (LTD and epileptiform studies)

All animals used in these studies were cared for in accordance with the NIH Guide for the Care and Use of Laboratory Animals. 30–40 (LTD experiments) or 24–30 (epileptiform experiments) day old male Sprague–Dawley rats were used. The brains were quickly removed and submerged into ice-cold cutting solution (in mM: 110 sucrose, 60 NaCl, 3 KCl, 1.25 NaH₂PO₄, 28 NaHCO₃, 5 glucose, 0.6 (+)-sodium-L-ascorbate, 0.5 CaCl₂, 7 MgCl₂). All solutions were continuously bubbled with 95% O₂/5% CO₂. Transverse slices (400 μ m) were made using a vibratome (Leica VT100S). For LTD experiments, individual hippocampi were microdissected out and transferred to a room temperature mixture containing equal volumes of cutting solution and artificial cerebrospinal fluid (ACSF; in mM: 125 NaCl, 2.5 KCl, 1.25 NaH₂PO₄, 25 NaHCO₃, 25 glucose, 2 CaCl₂, 1 MgCl₂) and equilibrated for 30 min, followed by room temperature ACSF for 1 h. For epileptiform experiments, individual hippocampi were transferred directly into room temperature ACSF (in mM: 124 NaCl, 5 KCl, 1.25 NaH₂PO₄, 26 NaHCO₃, 10 glucose, 2 CaCl₂, 1.2 MgSO₄) and equilibrated for 1 h. Slices were transferred to a submersion recording chamber and equilibrated for 5–10 min at 30–32°C. A bipolar-stimulating electrode was placed in the stratum radiatum near the CA3-CA1 border in order to stimulate the Schaffer collaterals. Recording electrodes were filled with ACSF and placed in the stratum radiatum of area CA1 (LTD experiments) or in the pyramidal cell body layer of CA3 (epileptiform experiments). Field potential recordings were acquired using a Multiclamp 700B (Warner Instruments) amplifier and pClamp 9.2 software. For stimulation based experiments an intensity that produced 50–60% of the maximum was used as the baseline stimulation. mGlu₅ compounds were diluted to the appropriate concentrations in DMSO and applied to the bath using a perfusion system. Sampled data was analyzed by averaging three sequential field excitatory postsynaptic potentials (fEPSPs) slopes, followed by normalizing to the average slope calculated during the predrug period (percent of baseline). For epileptiform experiments, spontaneous events were measured using MiniAnalysis (Synaptosoft Inc, NJ) and inter-event interval (IEI) was normalized to the baseline response.

Comparative modeling of receptor

The comparative model of mGlu₅ was constructed as described previously (Gregory et al., 2013). In brief, the X-ray crystal structure for human β 2-adrenergic receptor (PDB ID: 2RH1)⁵⁰ was chosen as a template based on its high sequence similarity to mGlu₅. A profile to profile sequence alignment of TM regions between Class C hepta-helical transmembrane regions and Class A crystal structure templates was directly adopted from Muhlemann et al., 2006,⁵⁰ with the exception of TM2, TM4 and TM7, which were based on the alignment of CaSR with Class A hepta-helical regions.⁵¹ The sequence alignment was used to thread the amino acid sequence of the mGlu₅ transmembrane helical region onto the backbone coordinates of the β 2-adrenergic receptor. The protein structure prediction software package Rosetta 3.4⁵¹ was used to rebuild the loop regions between the helices using Monte Carlo Metropolis (MCM) fragment replacement combined with cyclic coordinate descent loop closure (CCD).^{53,54} The resulting full sequence models were then subjected to eight iterative cycles of side chain repacking and gradient minimization of ϕ , ψ and χ angles in Rosetta Membrane.⁵⁶ Over 5,000 comparative models of mGlu₅ were generated and clustered for structural similarity using bcl::Cluster.⁵⁷ The lowest energy model from the largest cluster was used for further ligand docking studies.

Computational docking of ligands

Ligands **19**, **38t** and **31i** were computationally docked into the comparative model of mGlu₅ using Rosetta Ligand.^{57–59} Each modulator was allowed to sample docking poses in a 5 Å radius centered at the putative binding site for allosteric modulation, determined by the

residues known to affect MPEP affinity.⁴⁷ Once a binding mode had been determined by the docking procedure, 10 low energy conformations of the ligand created by MOE (Molecular Operating Environment, Chemical Computing Group, Ontario, Canada) were tested within the site. Side-chain rotamers around the ligand were optimized simultaneously in a Monte-Carlo minimization algorithm. The energy function used during the docking procedure contains terms for van der Waals attractive and repulsive forces, hydrogen bonding, electrostatic interactions between pairs of amino acids, solvation, and a statistical term derived from the probability of observing a side-chain conformation from the Protein Data Bank. For each modulator, over 5,000 docked complexes were generated and clustered for structural similarity using bcl::Cluster.⁵⁷ The lowest energy binding mode from the two largest clusters for each modulator, encompassing ligand positions for which the eastern amide was pointing either towards or away from the extracellular surface, were used for further analysis.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

E.D.N. funding is provided by the Public Health Service award T32 GM07347 from the National Institute of General Medical Studies for the Vanderbilt Medical-Scientist Training Program (MSTP) and the Paul Calabresi Medical Student Research Fellowship from the Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation. This work was supported in part by grants from the NIH (NS031373 and MH062646). Vanderbilt is a member of the MLPCN and houses the Vanderbilt Specialized Chemistry Center for Accelerated Probe Development (U54MH084659).

ABBREVIATIONS USED

mGlu	metabotropic glutamate receptor
PAM	positive allosteric modulator
NAM	negative allosteric modulator
SAM	silent allosteric modulator
PCP	phenylcyclidine
NMDAR	ionotropic N-Methyl-D-aspartate glutamate receptor
DHPG	dihydroxyphenylglycine
LTD	long-term depression
MTEP	3-((2-methyl-4-thiazolyl)ethynyl)pyridine
MPEP	2-methyl-6-(phenylethynyl)pyridine
DFB	3, 3'-difluorobenzaldazine
CPPHA	<i>N</i> -(4-chloro-2-((1,3-dioxoisindolin-2-yl)methyl)phenyl)-2-hydroxybenzamide
CDPPB	3-cyano- <i>N</i> -(1,3-diphenyl-1 <i>H</i> -pyrazol-5-yl)benzamide
AHL	amphetamine-induced hyperlocomotion
MWM	Morris water maze
MAM	methylazoxymethanol

EEG	electroencephalogram
DMTP	delayed-matching-to-position
MLPCN	molecular libraries probe production centers network

REFERENCES

1. Chavez-Noriega LE, Marino MJ, Schaffhauser H, Campbell UC, Conn PJ. Novel Potential Therapeutics for Schizophrenia: Focus on the Modulation of Metabotropic Glutamate Receptor Function. *Curr. Neuropharm.* 2005; 3:9–34.
2. Lindsley CW, Shipe WD, Wolkenberg SE, Theberge CR, Williams DL Jr, Sur C, Kinney GG. Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. *Curr. Top. Med. Chem.* 2006; 6:771–785. [PubMed: 16719816]
3. Lisman JE, Coyle JT, Green RW, Javitt DC, Benes FM, Heckers S, Grace AA. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. *Trends Neurosci.* 2008; 31:234–242. [PubMed: 18395805]
4. Conn PJ, Lindsley CW, Jones CK. Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. *Trends Pharmacol. Sci.* 2009; 30:25–31. [PubMed: 19058862]
5. Toda M, Abi-Dargham A. Dopamine hypothesis of schizophrenia: making sense of it all. *Curr. Psychiatry Rep.* 2007; 9:329–336. [PubMed: 17880866]
6. Stahl SM. Beyond the dopamine hypothesis to the NMDA glutamate receptor hypofunction hypothesis of schizophrenia. *CNS Spectr.* 2007; 12:265–268. [PubMed: 17426663]
7. Stargardt T, Weinbrenner S, Busse R, Juckel G, Gericke CA. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care. *J. Ment. Health. Policy. Econ.* 2008; 11:89–97. [PubMed: 18509216]
8. Crossley NA, Constante M, McGuire P, Power P. Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. *Br. J. Psychiatry.* 2010; 196:434–439. [PubMed: 20513851]
9. Coyle JT. Glutamate and schizophrenia: beyond the dopamine hypothesis. *Cell. Mol. Neurobiol.* 2006; 26:365–384. [PubMed: 16773445]
10. Lewis DA, Moghaddam B. Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. *Arch. Neurol.* 2006; 63:1372–1376. [PubMed: 17030651]
11. Carlsson A. The Neurochemical Circuitry of Schizophrenia. *Pharmacopsychiatry.* 2006; 39:S10–S14. [PubMed: 16508890]
12. Marek GJ, Behl B, Beshpalov AY, Gross G, Lee Y, Schoemaker H. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain? *Mol. Pharmacol.* 2010; 77:317–326. [PubMed: 19933774]
13. Niswender CM, Conn JP. Metabotropic Glutamate Receptors: Physiology, Pharmacology, and Disease. *Annu. Rev. Pharmacol. Toxicol.* 2010; 50:295–322. [PubMed: 20055706]
14. Heresco-Levy U, Ermilov M, Shimoni J, Shapira B, Silipo G, Javitt DC. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. *Am. J. Psychiatry.* 2002; 159:480–482. [PubMed: 11870017]
15. Javitt DC, Silipo G, Cienfeugos A, Shelley AM, Bark N, Park M, Lindenmayer JP, Suckow R, Zukin SR. Adjunctive high-dose glycine in the treatment of schizophrenia. *Int. J. Neuropsychopharmacol.* 2001; 4:385–391. [PubMed: 11806864]
16. Lindsley CW, Stauffer SR. Metabotropic glutamate receptor 5-positive allosteric modulators for the treatment of schizophrenia (2004–2012). *Pharm. Pat. Analyst.* 2013; 2:93–108.
17. Stauffer SR. Progress toward Positive Allosteric Modulators of the Metabotropic Glutamate Receptor Subtype 5 (mGlu₅). *ACS Chem. Neurosci.* 2011; 2:450–470. [PubMed: 22860171]

18. Bridges TM, Lindsley CW. G-protein-coupled receptors: from classical modes of modulation to allosteric mechanisms. *ACS Chem. Biol.* 2008; 3:530–541. [PubMed: 18652471]
19. Conn PJ, Christopoulos A, Lindsley CW. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. *Nat. Rev. Drug Discov.* 2009; 8:41–54. [PubMed: 19116626]
20. Melancon BJ, Hopkins CR, Wood MR, Emmitte KA, Niswender CM, Christopoulos A, Conn PJ, Lindsley CW. Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. *J. Med. Chem.* 2012; 55:1445–1464. [PubMed: 22148748]
21. O'Brien JA, Lemaire W, Wittmann M, Jacobson MA, Ha SN, Wisnoski DD, Lindsley CW, Schaffhauser HJ, Rowe B, Sur C, Duggan ME, Pettibone DJ, Conn PJ, Williams DL Jr. A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain. *J. Pharmacol. Exp. Ther.* 2004; 309:568–577. [PubMed: 14747613]
22. Lindsley CW, Wisnoski DD, Leister WH, O'Brian JA, Lemair W, Williams DL Jr, Burno M, Sur C, Kinney GG, Pettibone DJ, Tiller PR, Smith S, Duggan ME, Hartman GD, Conn PJ, Huff JR. Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides that potentiate receptor function in vivo. *J. Med. Chem.* 2004; 47:5825–5828. [PubMed: 15537338]
23. Kinney GG, O'Brian JA, Lemaire W, Burno M, Bickel DJ, Clements MK, Chen TB, Wisnoski DD, Lindsley CW, Tiller PR, Smith S, Jacobson MA, Sur C, Duggan ME, Pettibone DJ, Conn PJ, Williams DL Jr. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. *Pharmacol. Exp. Ther.* 2005; 313:199–206.
24. Liu F, Grauer S, Kelley C, Navarra R, Graf R, Zhang G, Atkinson PJ, Popiolek M, Wantuch C, Khawaja X, Smith D, Olsen M, Kouranova E, Lai M, Pruthi F, Pulicicchio C, Day M, Gilbert A, Pausch MH, Brandon NJ, Beyer CE, Comery TA, Logue S, Rosenzweig-Lipson S, Marquis KL. ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. *J. Pharmacol. Exp. Ther.* 2008; 327:827–839. [PubMed: 18753411]
25. Spear N, Gadiant RA, Wilkins DE, Do M, Smith JS, Zeller KL, Schroeder P, Zhang M, Arora J, Chhajlani V. CPPZ. Preclinical profile of a novel metabotropic glutamate receptor 5 positive allosteric modulator. *Eur. J. Pharmacol.* 2011; 659:146–154. [PubMed: 21335002]
26. Packiarajan M, Mazza Ferreira CG, Hong SP, White AD, Chandrasena G, Pu X, Brodbeck RM, Robichaud AJ. N-Aryl pyrrolidinonyl oxadiazoles as potent mGlu5 positive allosteric modulators. *Bioorg. Med. Chem. Lett.* 2012; 22:5658–5662. [PubMed: 22832311]
27. Packiarajan M, Ferreira CG, Hong SP, White AD, Chandrasena G, Pu X, Brodbeck RM, Robichaud AJ. Azetidinyloxadiazoles as potent mGlu5 positive allosteric modulators. *Bioorg. Med. Chem. Lett.* 2012; 22:6469–6474. [PubMed: 22975301]
28. Gilmour G, Broad LM, Wafford KA, Britton T, Colvin EM, Fivush A, Gastambide F, Getman B, Heinz BA, McCarthy AP, Prieto L, Shanks E, Smith JW, Taboada L, Edgar DM, Tricklebank MD. In vitro characterisation of the novel positive allosteric modulators of the mGlu₅ receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat. *Neuropharmacology.* 2013; 64:224–239. [PubMed: 22884720]
29. Vanejevs M, Jatzke C, Renner S, Müller S, Hechenberger M, Bauer T, Klochkova A, Pyatkin I, Kazyulkin D, Aksenova E, Shulepin S, Timonina O, Haasis A, Gutcaits A, Parsons CG, Kauss V, Weil T. Positive and negative modulation of group I metabotropic glutamate receptors. *J. Med. Chem.* 2008; 51:634–647. [PubMed: 18173231]
30. Sharma S, Kedrowski J, Rook JM, Smith RL, Jones CK, Rodriguez AL, Conn PJ, Lindsley CW. Discovery of molecular switches that modulate modes of metabotropic glutamate receptor subtype 5 (mGlu₅) pharmacology in vitro and in vivo within a series of functionalized, regioisomeric 2- and 5-(phenylethynyl)pyrimidines. *J. Med. Chem.* 2009; 52:4103–4106. [PubMed: 19537763]
31. Ritzén A, Sindet R, Hentzer M, Svendsen N, Brodbeck RM, Bundgaard C. Discovery of a potent and brain penetrant mGlu₅ positive allosteric modulator. *Bioorg. Med. Chem. Lett.* 2009; 19:3275–3278. [PubMed: 19443216]

32. Varnes JG, Marcus AP, Mauger RC, Throner SR, Hoesch V, King MM, Wang X, Sygowski LA, Spear N, Gadiant R, Brown DG, Campbell JB. Discovery of novel positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5). *Bioorg. Med. Chem. Lett.* 2011; 21:1402–1406. [PubMed: 21295468]
33. Bartolomé-Nebreda JM, Conde-Ceide S, Delgado F, Iturrino L, Pastor J, Pena MA, Trabanco AA, Tresadern G, Wassvik CM, Stauffer SR, Jadhav S, Gogi K, Vinson PN, Days E, Weaver CD, Lindsley CW, Niswender CM, Jones CK, Conn PJ, Rombouts F, Lavreysen H, Macdonald GJ, Mackie C, Steckler T. Dihydrothiazolopyridone Derivatives as a Novel Family of Positive Allosteric Modulators of the mGlu5 Receptor. *J. Med. Chem.* 2013
34. Manka JT, Vinson PN, Gregory KJ, Zhou Y, Williams R, Gogi K, Days E, Jadhav S, Herman EJ, Lavreysen H, Mackie C, Bartolomé JM, MacDonald GJ, Steckler T, Daniels JS, Weaver CD, Niswender CM, Jones CK, Conn PJ, Lindsley CW, Stauffer SR. Optimization of an ether series of mGlu5 positive allosteric modulators: molecular determinants of MPEP-site interaction crossover. *Bioorg. Med. Chem. Lett.* 2012; 22:6481–6485. [PubMed: 22981332]
35. Hammond AS, Rodriguez AL, Townsend SD, Niswender CM, Gregory KJ, Lindsley CW, Conn PJ. Discovery of a Novel Chemical Class of mGlu(5) Allosteric Ligands with Distinct Modes of Pharmacology. *ACS Chem. Neurosci.* 2010; 1:702–716. [PubMed: 20981342]
36. Ayala JE, Chen Y, Banko JL, Sheffler DJ, Williams R, Telk AN, Watson NL, Xiang Z, Zhang Y, Jones PJ, Lindsley CW, Olive MF, Conn PJ. mGlu5 Positive Allosteric Modulators Facilitate both Hippocampal LTP and LTD and Enhance Spatial Learning. *Neuropsychopharmacology.* 2009; 34:3057–3071.
37. Rook JM, Noetzel MJ, Pouliot WA, Bridges TM, Vinson PN, Cho HP, Zhou Y, Gogliotti RD, Manka JT, Gregory KJ, Stauffer SR, Dudek FE, Xiang Z, Niswender CM, Daniels JS, Jones CK, Lindsley CW, Conn PJ. Unique Signaling Profiles of Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Determine Differences in In Vivo Activity. *Biol. Psychiatry.* 2013; 73:501–509. [PubMed: 23140665]
38. Bridges TM, Rook JM, Noetzel MJ, Morrison RD, Zhou Y, Gogliotti RD, Vinson PN, Jones CK, Niswender CM, Lindsley CW, Stauffer SR, Conn PJ, Daniels JS. Biotransformation of a Novel Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Contributes to Seizure-Like Adverse Events in Rats Involving a Receptor Agonism-Dependent Mechanism. *Drug Metab. Dispos.* 2013; 41:703–714.
39. Parmentier-Batteur S, Hutson PH, Menzel K, Uslaner JM, Mattson BA, O'Brien JA, Magliaro BC, Forest T, Stump CA, Tynebor RM, Anthony NJ, Tucker TJ, Zhang XF, Gomez R, Huszar SL, Lambeng N, Fauré H, Le Poul E, Poli S, Rosahl TW, Rocher JP, Hargreaves R, Williams TM. Mechanism based neurotoxicity of mGlu5 positive allosteric modulators—Development challenges for a promising novel antipsychotic target. *Neuropharmacology.* 2013
40. Merlin LR, Wong RK. Role of group I metabotropic glutamate receptors in the patterning of epileptiform activities in vitro. *J. Neurophysiol.* 1997; 78:539–44. [PubMed: 9242303]
41. Wong RK, Bianchi R, Chuang SC, Merlin LR. Group I mGlu-induced epileptogenesis: distinct and overlapping roles of mGlu1 and mGlu5 and implications for antiepileptic drug design. *Epilepsy Curr.* 2005; 5:63–68. [PubMed: 16059439]
42. Rodriguez AL, Grier MD, Jones CK, Herman EJ, Kane AS, Smith RL, Williams R, Zhou Y, Marlo JE, Days EL, Blatt TN, Jadhav S, Menon UN, Vinson PN, Rook JM, Stauffer SR, Niswender CM, Lindsley CW, Weaver CD, Conn PJ. Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. *Mol. Pharmacol.* 2010; 78:1105–1123. [PubMed: 20923853]
43. Noetzel MJ, Rook JM, Vinson PN, Cho HP, Days E, Zhou Y, Rodriguez AL, Lavreysen H, Stauffer SR, Niswender CM, Xiang Z, Daniels JS, Jones CK, Lindsley CW, Weaver CD, Conn PJ. Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function. *Mol. Pharmacol.* 2012; 81:120–133. [PubMed: 22021324]
44. Sams AG, Mikkelsen GK, Brodbeck RM, Pu X, Ritzen A. Efficacy switching SAR of mGlu5 allosteric modulators: highly potent positive and negative modulators from one chemotype. *Bioorg. Med. Chem. Lett.* 2011; 21:3407–3410. [PubMed: 21531137]

45. (a) Wuitschik G, Carreira EM, Wanger B, Fischer H, Parrilla I, Schuler F, Rogers-Evans M, Müller K. Oxetanes in Drug Discovery: Structural and Synthetic Insights. *J. Med. Chem.* 2010; 53:3227–3246. [PubMed: 20349959] (b) Burkhard JA, Wuitschik G, Rogers-Evans M, Müller K, Carreira EM. Oxetanes as Versatile Elements in Drug Discovery and Synthesis. *Angew. Chem. Int. Ed.* 2010; 49:9052–9067.
46. Gregory KJ, Noetzel MJ, Rook JM, Vinson PN, Stauffer SR, Rodriguez AL, Emmitte KA, Zhou Y, Chun AC, Felts AS, Chauder BA, Lindsley CW, Niswender CM, Conn PJ. Investigating metabotropic glutamate receptor 5 allosteric modulator cooperativity, affinity, and agonism: enriching structure-function studies and structure-activity relationships. *Mol. Pharmacol.* 2012; 82:860–875. [PubMed: 22863693]
47. Gregory KJ, Nguyen ED, Reiff SD, Squire EF, Stauffer SR, Lindsley CW, Meiler J, Conn PJ. Probing the Metabotropic Glutamate Receptor 5 (mGlu5) Positive Allosteric Modulator (PAM) Binding Pocket: Discovery of Point Mutations that Engender a “Molecular Switch” in PAM Pharmacology. *Mol Pharmacol.* 2013; 83:991–1006. [PubMed: 23444015]
48. Merlin LR, Bergold PJ, Wang M, Wong RK. Requirement of protein synthesis for group I mGluR-mediated induction of epileptiform discharges. *J. Neurophysiol.* 1998; 80:989–993. [PubMed: 9705485]
49. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thain FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, Stevens RC. High-resolution crystal structure of an engineered human 2-adrenergic G protein coupled receptor. *Science.* 2007; 318:1258–1265. [PubMed: 17962520]
50. Mühlemann A, Ward NA, Kratochwil N, Diener C, Fischer C, Stucki A, Jaeschke G, Malherbe P, Porter RH. Determination of key amino acids implicated in the actions of allosteric modulation by 3, 3'-difluorobenzaldazine on rat mGlu5 receptors. *Eur. J. Pharmacol.* 2006; 529:95–104. [PubMed: 16352303]
51. Miedlich SU, Gama L, Seuwen K, Wolf RM, Breitwieser GE. Homology modeling of the transmembrane domain of the human calcium sensing receptor and localization of an allosteric binding site. *J. Biol. Chem.* 2004; 279:7254–7263. [PubMed: 14660633]
52. Leaver-Fay A, Tyka M, Lewis SM, Lange OF, Thompson J, Jacak R, Kaufman K, Renfrew PD, Smith CA, Sheffler W, Davis IW, Cooper S, Treuille A, Mandell DJ, Richter F, Ban YE, Fleishman SJ, Corn JE, Kim DE, Lyskov S, Berrondo M, Mentzer S, Popovic Z, Havranek JJ, Karanicolas J, Das R, Miler J, Kortemme T, Gray JJ, Kuhlman B, Baker D, Bradley P. ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. *Methods Enzymol.* 2011; 487:545–574. [PubMed: 21187238]
53. Wang C, Bradley P, Baker D. Protein-protein docking with backbone flexibility. *J. Mol. Biol.* 2007; 373:503–519. [PubMed: 17825317]
54. Canutescu AA, Dunbrack RL. Cyclic coordinate descent: a robotics algorithm for protein loop closure. *Protein Sci.* 2009; 12:963–972. [PubMed: 12717019]
55. Yarov-Yarovoy V, Schonbrun J, Baker D. Multipass membrane protein structure prediction using Rosetta. *Proteins.* 2005; 62:1010–1025. [PubMed: 16372357]
56. Alexander, N.; Woetzel, N.; Meiler, J. Bcl.: Cluster: A method for clustering biological molecules coupled with visualization in the Pymol Molecular Graphics System; Computational Advances in Bio and Medical Sciences (ICCABS). IEEE 1st International Conference; 2011. p. 13-18.
57. Meiler J, Baker D. RosettaLigand: Protein-small molecule docking with full side-chain flexibility. *Proteins.* 2006; 65:538–548. [PubMed: 16972285]
58. Davis IW, Baker D. RosettaLigand docking with full ligand and receptor flexibility. *J. Mol. Biol.* 2009; 385:381–392. [PubMed: 19041878]
59. Lemmon G, Meiler J. Rosetta Ligand docking with flexible XML protocols. *Methods Mol. Biol.* 2012; 819:143–155. [PubMed: 22183535]
60. For information on the MLPCN and information on how to request probe compounds, such as ML254, see: <http://mli.nih.gov/mli/mlpcn/>

Metabotropic Glutamate Receptor 5: **Orthosteric ligands:** **First Generation mGluR₅ PAMs:** **Figure 1.**

a. Representative mGlu₅ receptor (protomer of dimer) with orthosteric and allosteric binding sites. **b.** Orthosteric mGlu₅ ligands. **c.** 1st generation mGlu₅ PAMs.

N-Aryl Piperazines

8, CPPZ
EC₅₀ 550 nM (human)²⁵

N-Aryl Pyrrolidinones

9
EC₅₀ 11 nM (human)^{26,27}

Tetrahydrotriazolopyridines

10, LSN2814617
EC₅₀ 42 nM (rat), 52 nM (human)²⁸

Acetylenes

11
EC₅₀ 34 nM (rat), 172 nM (human)²⁹

12, MPPA
EC₅₀ 14 nM (rat)³⁰

13
EC₅₀ 30 nM (human)³¹

14 LSN2463359
EC₅₀ 24 nM (rat), 33 nm (human)²⁸

Ethers

15
EC₅₀ 50 nM (human)³²

16
EC₅₀ 1300 nM (rat)³³

17
EC₅₀ 2.2 nM (rat)³⁴

18, VU0357121
EC₅₀ 33 nM (rat)³⁵

Figure 2.
mGlu₅ PAM chemotypes and reported PAM potencies.

Figure 3.
Acetylene mGlu₅ PAMs used to assess seizure activity in animal models.^{37,38}

23, 5PAM523
Therapeutic Index: 2
Fold-shift: 11

24, 5PAM916
Therapeutic Index: 18
Fold-shift: 6

Figure 4.
Merck-Addex compounds found to induce neurotoxicity.³⁹

Figure 5. SAR development of Vanderbilt acetylene mGlu₅ PAMs. (Potency values refer to the low density rat mGlu₅ receptor cell line.⁴³)

Figure 6.

a. PAM to NAM mode switching with incorporation of the 2-pyridyl motif.^{29,44} b. Acetylene based allosteric antagonists.

Figure 7.
Oxetane surrogate for steric bulk with decreased lipophilicity.

Figure 8. mGlu₅ binding pose for pure-PAMs **31i** (cyan color) and **38t** (green color) and ago-PAM **19** (magenta).

Figure 9.
38t fully displaces $[^3\text{H}]$ methoxyPEPy binding.

Figure 10.

38t shifts the glutamate concentration response curve leftward with increasing concentrations of modulator: 1.7 at 50 nM; 1.7 at 100 nM; 2.2 at 500 nM; 2.7 at 1 μ M; 3.0 at 5 μ M; 2.8 at 10 μ M and 3.2 at 30 μ M

Figure 11.
38t has no effect on long-term depression at the SC-CA1 synapse in rat hippocampus.

scheme 1. Synthesis of (*R*)-3-amino-2-methylbutan-2-ol^a

^aReagents and conditions: (a) SOCl₂, MeOH, 0 °C to rt; (b) Boc₂O, Et₃N, CH₂Cl₂, 0 °C to rt, 88% over 2 steps; (c) MeMgBr (3.0 equiv), THF, 0 °C to rt, 63%; (d) TFA/CH₂Cl₂ (1:2), 0 °C, 97%.

scheme 2. Synthesis of western aryl analogs^a

^aReagents and conditions: (a) **29**, HATU, DIPEA, DMF, rt, 81% (b) terminal acetylene, CuI, PdCl₂(PPh₃)₂, Et₂NH, DMF, 90 °C, 50–90%; (c) trimethylsilylacetylene, CuI, PdCl₂(PPh₃)₂, Et₂NH, DMF, 90 °C, 77%; (d) K₂CO₃, MeOH/THF, rt, 95%; (e) aryl bromide, CuI, PdCl₂(PPh₃)₂, Et₂NH, DMF, 90 °C, 43–62%.

scheme 3. Synthesis of core analogs^a

^aReagents and conditions: (a) 1-ethynyl-3-fluorobenzene, CuI, PdCl₂(PPh₃)₂, Et₂NH, DMF, 90 °C, 30–97%; (b) **29**, HATU, DIPEA, DMF, rt, (c) LiOH, THF/H₂O, rt.

scheme 4. Synthesis of eastern amide analogs^a

^aReagents and conditions: (a) 1-ethynyl-3-fluorobenzene, CuI, PdCl₂(PPh₃)₂, Et₂NH, DMF, 90 °C, 65%; (b) amine, HATU, DIPEA, DMF, rt; (c) NaH, MeI, THF, 0 °C to rt, 58%; (d) DAST, CH₂Cl₂, -78 °C to rt, 30%.

Table 1

Rat mGlu₅ Potency and % GluMax Response for Western Aryl Analogs

Compound	R	Potentiator (Rat mGlu ₅)			Agonist (Rat mGlu ₅)			Category	
		pEC ₅₀ (± SEM) ^a	EC ₅₀ (nM) ^a	GluMax (± SEM) ^a	pEC ₅₀ (± SEM) ^a	EC ₅₀ (nM) ^a	GluMax (± SEM) ^a		
31a		8.38 ± 0.14	4.1	60.9 ± 5.1	6.06 ± 0.14	874	43.2 ± 5.2	ago-PAM	
31b		8.10 ± 0.07	8.0	60.0 ± 2.9	5.94 ± 0.10	1,160	29.6 ± 4.0	ago-PAM	
19		8.31 ± 0.02	4.9	63.5 ± 2.7	6.04 ± 0.10	904	37.1 ± 5.7	ago-PAM	
31c		7.91 ± 0.07	12.3	66.2 ± 2.1	5.82 ± 0.12	1,520	38.4 ± 5.7	ago-PAM	
31d		7.24 ± 0.10	58.2	61.6 ± 1.4	5.44 ± 0.01	3,670	37.9 ± 4.3	ago-PAM	
31e		7.58 ± 0.09	26.6	61.2 ± 1.4	5.43 ± 0.18	3,690	38.2 ± 8.9	ago-PAM

Compound	R	Potentiator (Rat mGlu ₅)			Agonist (Rat mGlu ₅)			Category	
		pEC ₅₀ (± SEM) ^a	EC ₅₀ (nM) ^a	GluMax (± SEM) ^a	pEC ₅₀ (± SEM) ^a	EC ₅₀ (nM) ^a	GluMax (± SEM) ^a		
31f		6.66 ± 0.04	217	59.9 ± 1.8	4.91 ± 0.02	12,400	24.1 ± 5.3	ago-PAM	
31g		8.19 ± 0.16	6.5	68.6 ± 3.3	5.87 ± 0.03	1,360	20.8 ± 2.9	ago-PAM	
31h		6.97 ± 0.02	107	63.1 ± 2.0	--	--	--	PAM	
31i		7.38 ± 0.19	41.3	57.5 ± 6.14	--	--	--	PAM	
31j		6.46 ± 0.03	344	71.5 ± 4.4	5.03 ± 0.05	9,300	25.9 ± 8.3	ago-PAM	
31k		7.37 ± 0.13	43.0	66.6 ± 2.6	5.33 ± 0.06	4,660	22.4 ± 6.6	ago-PAM	
31l		7.23 ± 0.50	58.4	66.6 ± 3.0		--	--	PAM	
31m		5.89 ± 0.00	1289	63.4 ± 6.0	--	--	--	PAM

Agonist (Rat mGlu ₅)				
Compound	R	Potentiator (Rat mGlu ₅)						Category
31n		pEC ₅₀ (± SEM) ^a	EC ₅₀ (nM) ^a	GluMax (± SEM) ^a	pEC ₅₀ (± SEM) ^a	EC ₅₀ (nM) ^a	GluMax (± SEM) ^a	ago-PAM
		7.03 ± 0.28	93.3	63.7 ± 3.8	5.01 ± 0.06	9,750	14.8 ± 5.7	

^a pEC₅₀, EC₅₀, and % GluMax response are the average of at least three independent measurements performed in duplicate or triplicate.

Table 2

Rat mGlu₅ Potency and % GluMax Response for Core Analogs

Compound	R	Potentiator (Rat mGlu ₅)			Agonist (Rat mGlu ₅)			Category
		pEC ₅₀ (± SEM) ^a	EC ₅₀ (nM) ^a	GluMax (± SEM) ^a	pEC ₅₀ (± SEM) ^a	EC ₅₀ (nM) ^a	GluMax (± SEM) ^a	
36a		8.12 ± 0.06	7.5	53.9 ± 4.3	5.98 ± 0.03	1,040	43.6 ± 4.3	ago-PAM
19		8.31 ± 0.02	4.9	63.5 ± 2.7	6.04 ± 0.10	904	37.1 ± 5.7	ago-PAM
36b		7.10 ± 0.04	80.0	64.9 ± 1.5	5.17 ± 0.08	6,800	26.6 ± 5.1	ago-PAM
36c		7.77 ± 0.05	17.1	64.9 ± 2.1	5.96 ± 0.01	1,090	9.2 ± 1.7	ago-PAM
36d		6.98 ± 0.04	105.4	66.4 ± 3.2	--	--	--	PAM
36e		6.62 ± 0.04	242.1	66.6 ± 1.2	--	--	--	PAM

<div> </div>									
Compound	R	Potentiator (Rat mGlu ₅)			Agonist (Rat mGlu ₅)			Category	
		pEC ₅₀ (± SEM) ^a	EC ₅₀ (nM) ^a	GluMax (± SEM) ^a	pEC ₅₀ (± SEM) ^a	EC ₅₀ (nM) ^a	GluMax (± SEM) ^a		
36f		6.91 ± 0.13	121.8	68.7 ± 3.1	--	--	--	PAM	
36g		7.32 ± 0.18	47.6	64.1 ± 3.0	5.38 ± 0.22	4,130	19.2 ± 5.5	ago-PAM	
36h		7.66 ± 0.07	21.9	70.2 ± 3.4	5.67 ± 0.05	2,120	16.5 ± 3.9	ago-PAM	
36i		7.90 ± 0.03	12.5	64.4 ± 3.1	5.52 ± 0.02	3,040	17.2 ± 3.7	ago-PAM	
36j		7.48 ± 0.05	33.5	62.1 ± 3.8	5.32 ± 0.03	4,780	26.1 ± 2.9	ago-PAM	

^a pEC₅₀, EC₅₀, and % GluMax response are the average of at least three independent measurements performed in duplicate or triplicate.

Table 3Rat mGlu₅ Potency and % GluMax Response for Eastern Amide Analogs Lacking Polar Functionalities

Compound	R	Potentiator (Rat mGlu ₅)			Agonist (Rat mGlu ₅)			Category
		pEC ₅₀ (± SEM) ^a	EC ₅₀ (nM) ^a	GluMax (± SEM) ^a	pEC ₅₀ (± SEM) ^a	EC ₅₀ (nM) ^a	GluMax (± SEM) ^a
7.75 ± 0.19	17.8	66.0 ± 2.7	5.56 ± 0.07	2,751.8	31.2 ± 2.7	ago-PAM
	7.28 ± 0.12	51.9	70.8 ± 3.6	5.27 ± 0.17	5,403.4	20.0 ± 2.8	ago-PAM
	8.35 ± 0.09	4.5	69.3 ± 0.8	5.83 ± 0.25	1,469.1	22.5 ± 1.4	ago-PAM
	7.69 ± 0.11	20.4	66.7 ± 2.7	5.65 ± 0.04	2,224.1	13.1 ± 1.4	ago-PAM
	8.28 ± 0.04	5.3	68.6 ± 3.0	5.69 ± 0.08	2,064.5	42.8 ± 2.5	ago-PAM
	---	---	---	---	---	---	Inactive
	7.46 ± 0.04	34.4	65.9 ± 1.3	5.52 ± 0.03	3,009.9	8.3 ± 2.2	ago-PAM

Compound	R	Potentiator (Rat mGlu ₅)			Agonist (Rat mGlu ₅)			Category	
		pEC ₅₀ (± SEM) ^a	EC ₅₀ (nM) ^a	GluMax (± SEM) ^a	pEC ₅₀ (± SEM) ^a	EC ₅₀ (nM) ^a	GluMax (± SEM) ^a		
38h		7.54 ± 0.03	28.9	58.2 ± 2.7	--	--	--	PAM	
38i		7.78 ± 0.13	16.6	63.9 ± 1.0	5.59 ± 0.25	2,573.1	9.5 ± 2.1	ago-PAM	
38j		7.43 ± 0.10	36.7	61.4 ± 1.6	--	--	--	PAM	
38k		7.08 ± 0.12	84.0	68.1 ± 3.44	< 5.0	> 10,000.0	4.7 ± 1.3	ago-PAM	

^a pEC₅₀, EC₅₀, and % GluMax response are the average of at least three independent measurements performed in duplicate or triplicate.

Table 4Rat mGlu₅ Potency and % GluMax Response for Eastern Amide Analogs Bearing Polar Functionalities

Compound	R	Potentiator (Rat mGlu ₅)			Agonist (Rat mGlu ₅)			Category
		pEC ₅₀ (± SEM) ^a	EC ₅₀ (nM) ^a	GluMax (± SEM) ^a	pEC ₅₀ (± SEM) ^a	EC ₅₀ (nM) ^a	GluMax (± SEM) ^a	
19		8.31 ± 0.02	4.9	63.5 ± 2.7	6.04 ± 0.10	904	37.1 ± 5.7	ago-PAM
38l		--	--	--	--	--	--	Inactive
38m		8.10 ± 0.11	7.9	60.9 ± 4.6	6.14 ± 0.10	729	9.3 ± 3.3	ago-PAM
38n		7.46 ± 0.02	34.6	61.5 ± 2.5	5.40 ± 0.08	4,020	20.0 ± 6.0	ago-PAM
38o		--	--	--	--	--	--	Inactive
38p		6.87 ± 0.04	136	61.9 ± 2.8	--	--	--	PAM
38q		6.65 ± 0.09	224	67.0 ± 1.7	4.97 ± 0.22	10,700	5.8 ± 1.1	ago-PAM

Compound	R	Potentiator (Rat mGlu ₅)			Agonist (Rat mGlu ₅)			Category	
		pEC ₅₀ (± SEM) ^a	EC ₅₀ (nM) ^a	GluMax (± SEM) ^a	pEC ₅₀ (± SEM) ^a	EC ₅₀ (nM) ^a	GluMax (± SEM) ^a		
38r		7.68 ± 0.11	20.8	52.1 ± 7.1	--	--	--	PAM	
38s		7.66 ± 0.03	21.9	60.8 ± 4.7	5.86 ± 0.01	1,390	21.4 ± 2.2	ago-PAM	
38t		8.03 ± 0.06	9.3	45.5 ± 2.4	--	--	--	PAM	
38u		7.97 ± 0.23	10.7	60.4 ± 3.4	--	--	--	PAM	
38v		7.33 ± 0.11	47.3	65.7 ± 5.0	5.55 ± 0.03	2,840	16.3 ± 2.5	ago-PAM	

^a pEC₅₀, EC₅₀, and % GluMax response are the average of at least three independent measurements performed in duplicate or triplicate.

Compd	R ₁	R ₁	Potentiator (Rat mGlu ₅)			Agonist (Rat mGlu ₅)			Category
			pEC ₅₀ (± SEM) ^a	EC ₅₀ (nM) ^a	GluMax (± SEM) ^a	pEC ₅₀ (± SEM) ^a	EC ₅₀ (nM) ^a	GluMax (± SEM) ^a	
44b			7.10 ± 0.07	79.0	58.5 ± 3.0	--	--	--	PAM
44c			7.65 ± 0.10	22.2	54.9 ± 3.3	--	--	--	PAM
44d			6.14 ± 0.20 ^b	731 ^b	16.7 ± 4.5 ^b	--	--	--	antagonist
45			6.16 ± 0.10	691	36.0 ± 6.9	--	--	--	Weak PAM

^a pEC₅₀, EC₅₀, and % GluMax response are the average of at least three independent measurements performed in duplicate or triplicate.

^b pIC₅₀, IC₅₀, and GluMin are the average of three independent measurements performed in triplicate.

Table 6
Rat mGlu₅ Cooperativity (Fold-Shift) of Selected PAMs Lacking Apparent Allosteric Agonist Activity.

Compound	Structure	Glutamate Fold-Shift	Compound	Structure	Glutamate Fold-Shift
31i		1.7	38p		5.3
31l		1.6	38r		1.5
36d		2.3	38t		2.8
36f		4.0	38u		3.3
38h		1.9	44b		1.3

Compound	Structure	Glutamate Fold-Shift	Compound	Structure	Glutamate Fold-Shift
38j		1.6	44c		1.5

^aPAM concentration tested was 10 μ values represent the average of three independent measurements performed in triplicate.